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1 INTRODUCTION 
 A comparison between the average life span of German people today and roughly 100 years 
ago would reveal something very obvious: The life span has increased by more than a 100% 
from 37 years in 1880 to 78 years in 2004* due to improved living conditions. However, this 
change comes at the cost of side effects, e.g. age-related disorders such as coronary artery 
disease (CAD). Atherosclerosis is the underlying cause of most CAD and this group of 
diseases is the main cause of death in the Western world today.1 Therefore understanding 
how atherosclerosis develops and which immune mechanisms are involved represents one 
way of fighting its consequences. The following introduction will give a short overview on how 
our immune system is built up, how different cell types influence the immune response – 
highlighting the role of neutrophils and plasmacytoid dendritic cells – and how atherosclerosis 
develops. 
1.1 THE IMMUNE SYSTEM 
Constant exposure to harmful omnipresent pathogens in our environment is one of the 
greatest challenges for all living organisms. To prevent pathogen invasion every organism has 
its natural barriers which have to be constantly monitored. To keep these borders protected an 
immune system has evolved, which is able to rapidly eliminate invading pathogens. To fulfill 
this task, the immune system of vertebrates offers two ways of response: Innate and 
Adaptiveimmunity.2 Innate immunity detects distinct molecular patterns of pathogens 
(PAMPs: pathogen-associated molecular patterns) with various pattern recognition receptors 
(PRR), such as Toll-like receptors (TLRs). Among the cells that express PRRs are 
macrophages, dendritic cells (DCs), mast cells, neutrophils, eosinophils, and NK cells. 
Pathogen exposure activates these cells, which in turn induce a rapid inflammatory response 
to eliminate the intruder.3 However, if the innate immune system is unable toclear the 
infection, activation of an adaptive immune response becomes necessary. Adaptive immune 
responses are initiated by specialized antigen-presenting cells, most importantly by DCs, via 
presentation of pathogen derived peptides (antigens) to B- and T-cells. This leads to an 
activation of B- and T-cells, which have the unique ability to express receptors that are not 
encoded in the germ line, but can be generated de novo from rearranged gene segments. 
This mechanism allows a great variability in adaptive immune recognition by offering an 
almost unlimited repertoire of antigen receptors which enables the immune system to create a 
                                               
*
 Average of men and women together, source: www.zdwa.de 
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specific immune response to virtually any pathogen present. Activated T cells release specific 
sets of cytokines inducing a cell-mediated immune response, while activated B cells produce 
antibodies as part of a humoral immune response.4,5 However, adaptive immunity requires the 
innate arm to orchestrate its response to guarantee an optimal host defense, emphasizing that 
two players are needed to build up a working team. 
1.2 CELLS OF THE IMMUNE SYSTEM 
Innate as well as adaptive immunity relies on leukocytes (white blood cells) which originate 
from hematopoietic stem cells (HSC) located in the bone marrow. These HSCs differentiate 
further into common myeloid (CMP) and lymphoid progenitors (CLP).6 Among others CMPs 
are the precursors of macrophages, granulocytes (including neutrophils), dendritic cells, and 
megakaryocytes which are all part of the innate immune system. Instead CLPs give rise to B 
cells and T cells, which build up adaptive immunity. As an exception CMPs and CLPs can 
both develop into dendritic cells, which may underline their important relevance at the border 
of innate and adaptive immunity (Figure 1-1).7,8 
 
1.2.1 NEUTROPHILS 
Neutrophils belong to a group of white blood cells referred to as granulocytes also including 
eosinophils and basophils. The discovery of granulocytes dates back to the German Nobel 
laureate Paul Ehrlich, who already realized in 1900 the functional potential of the granule 
contents in the inflammatory process: “… it is likely that the leukocyte granulations are in fact 
secretory products, which the cell dissolves and spreads to the environment as needed”.9 
Hence, PMN are characterized by granules in their cytoplasm and multilobed nuclei, the 
reason why they are as well called polymorphnuclear leukocytes (PMN). Of note, PMN may 
also abbreviate for polymorphnuclear neutrophil, which is used as a synonym for the term 
“neutrophil” throughout this work. Neutrophils are the most abundant cell type in humans 
making up to 70% of the normal leukocyte blood count. In contrast mice only show up to 25% 
PMNs in leukocyte counts of normal peripheral blood.10,11 It is not clear how this difference 
can be explained and neutrophils seem to cover the same functions in both organisms.12 
PMNs are professional phagocytes that are able to take up and destroy infectious agents 
(mostly bacteria) by releasing the contents of their granules into the phagosome accompanied 
by the production of reactive oxygen species (ROS). In addition to the phagocytic activity, 
PMN are capable of forming neutrophil extracellular traps (NETs).  
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Figure1-1. Hematopoieses. Tree diagram, showing the development of different blood cells from 
HSCs via different progenitors into mature cells. Cells, which are important throughout this study, are 
marked by a red arrow. Abbreviations: CDP, common DC progenitor; CMP, common myeloid 
progenitor; CLP, common lymphoid progenitor; GMP, granulocyte and macrophage progenitor; GP, 
granulocyte progenitor, HSC, hematopoietic stem cell; MDP, macrophage and DC progenitor; MEP, 
megakaryocyte and erythrocyte progenitor; MPP, multipotent progenitors. 
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These NETs are composed of neutrophil nuclear contents and e.g. serine proteases, which 
are one reason why NETs are able to kill bacteria extracellulary.13,14 Moreover PMN do also 
have the ability to generate chemokines (e.g. MIP-1α, IL-8)15,16 and proinflammatory cytokines 
(TNFα, IFNγ)17,18. However, neutrophil-mediated immune responses do not only have a 
beneficial impact but can also lead to tissue damage.19,20 Maturation of PMNs occurs in the 
bone marrow in about two weeks, a process in which the myeloid-specific growth factors G-
CSF and GM-CSF play an important role.10 Maturated neutrophils are stored in the bone 
marrow and have a high turnover once they enter the circulation (6-12 hours) until they 
migrate to tissue or undergo apoptosis. In general their life span does not exceed seven 
days.11 Retention of neutrophils from the bone marrow is tightly controlled by the stromal 
derived factor–1 (SDF-1) and its chemokine receptor CXCR4, whereas G-CSF induces 
neutrophil release from the bone marrow, in major part, by disrupting stromal derived factor-
1/CXCR4 signaling.21,22 Transcription of genes facilitating PMN development is controlled by 
PU.1 together with C/EBP(CCAAT/enhancer-binding protein)-α to the level of GMPs, while 
C/EBPε guides maturation along the granulocytic lineage (Figure 1-1). Instead, among others, 
interferon regulatory factor 8 (IRF8, also known as Interferon consensus sequence binding 
protein, ICSBP) is essential in directing monocyte and macrophage differentiation and 
represses genes promoting granulocytic differentiation and maturation.23 Human PMN can be 
distinguished from other leukocytes by their surface expression of CD17724 and CD1525, 
mouse neutrophils can be discriminated with antibodies against Ly6G (part of Gr1)26 and the 
exclusion of monocytes with an antibody against CD115.27 Additionally, both, human and 
mouse PMN appear very high in the sideward scatter if examined with flow cytometry, due to 
their high granularity.  
1.2.1.1 NEUTROPHIL GRANULE PROTEINS 
Granule proteins are key effectors in the immune response initiated by PMN and are released 
upon activation of the cell. Their subsets can be classified 
as primary, secondary, and tertiary granules, as well as 
secretory vesicles. This classification is based on the 
analysis of marker proteins, which differ between granule 
classes.  
Figure 1-2. Electron microscopy showing the various intra-
cytoplasmic granules of a resting neutrophil. Peroxidase-
positive granules are primary granules, (pg), which appear as 
large dark granules. Secondary granules(sg) are smaller in size. 
Nucleus (N); centriole (ce); mitochondria (m), (adapted from 
Witko-Sarsa et al.)
28
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Granule biogenesis proceeds sequentially during granulopoiesis and proteins are formed 
according to their numerical order (primary, secondary…).Instead, neutrophils on their way 
from blood to sites of infection release their granules in a hierarchical order (Figure 1-2)29-31: 
Secretory vesicles are characterized by their immediate release when contact is established 
between the PMN and the endothelium. Once a neutrophil transmigrates tertiary granules are 
mobilized, whereas secondary and primary granules are liberated at the site of inflammation. 
Thus granule proteins cover multiple tasks of neutrophil action, e.g. enabling PMN to 
extravasate tissue, kill microorganisms or affect surrounding inflammatory cells by deposition 
of granule proteins in extravascular spaces. Several constituents of neutrophil granules 
(underlined red in Figure 1-3) were found to be of essential importance during the course of 
the experimental progress of this thesis. Therefore, a brief summary of these granule proteins 
will follow: 
 
Figure 1-3. Granule subsets are released at different stages of PMN extravasation. PMNs migrate 
from the vasculature through a coordinated series of cell-cell and cell-matrix interactions. Granule 
subsets are thought to be released at distinct steps of PMN extravasation, thereby releasing granule 
proteins into the surroundings or presenting membrane-bound granule proteins on the PMN cell 
surface. Release of secretory vesicles following PMN adhesion leads to the deposition of azurocidin 
and proteinase-3 on the endothelial cell surface and incorporation of receptors (CD14, CD16, β2-
integrins) into the PMN cell surface. Transmigrating PMNs release tertiary granules, which contain 
proteases to help penetration of the basement membrane. The migrated PMNs deposit antimicrobial 
polypeptides (e.g. LL-37, azurocidin, HNPs) and proteases (e.g. cathepsin G, elastase) in the 
extravascular tissue, leading to interaction with nearby cells. Abbreviations: FPR, formyl peptide 
receptor; HNP, human neutrophil peptide;MMP-9, matrix metalloproteinase 9; MPO, myeloperoxidase; 
TNF-R, tumor necrosis factor receptor (adapted from Soehnlein et al.).
32
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LL-37 or CRAMP: LL-37/hCAP-18 is the only cathelicidin present in humans33, its proform is 
termed hCAP-18 and to be found in secondary granules (Figure 1-3) of PMN, LL-37 is the 
biological active C-terminal cleavage product of hCAP-18.34 Cathelin-related antimicrobial 
peptide (CRAMP) is the homologues molecule of LL-37 in mice showing very similar functions 
as its human counterpart.35 Besides the broad antimicrobial activity of LL-37/CRAMP against 
bacteria36, LL-37/CRAMP has gained attention for its immunomodulating properties37. Among 
others, LL-37 has been shown to be involved in chemoattraction of immune cells38,39, 
activation of Th-1 cytokine release by DCs40, and modulation of immune responses on 
monocytes and DCs to TLR-ligands41-43. 
Matrix Metalloproteinase-9: Matrix metalloproteinase-9 (MMP-9; gelatinase B) is a member 
of the MMP enzyme family, which is widely expressed in many tissues and cell types. Like 
other MMPs, MMP-9 mainly degrades components of the extracellular matrix, e.g. to enhance 
neutrophil attraction to chemokines.44,45 Furthermore, studies about its enzyme activity 
identified MMP-9 as an important target in inflammatory and vascular diseases.46 In PMN 
MMP-9 is stored in tertiary granules and exocytosis of these granules is initiated upon 
neutrophil transendothelial migration (Figure 1-3).32 
Myeloperoxidase: Myeloperoxidase (MPO) is a protein present in primary and secondary 
PMN granules (Figure 1-3). Once the PMN is activated MPO is released into the phagosome 
to amplify the toxic potential of H2O2. This amplification is mediated through the production of 
reactive intermediates of H2O2, such as hypochlorous acid, which is a potent oxidant of 
electron-rich substrates. These MPO-derived oxidants are also part of the respiratory burst, in 
which various reactive oxygen species are generated. Implications of MPO-derived oxidants 
are known for various inflammatory processes, also unrelated to host defense.47 
CD14/CD16: Cluster of Differentiation 14 (CD14) is a receptor of bacterial lipopolysaccharide 
(LPS) and described as a glycosylphosphatidylinositol (GPI)-anchored protein lacking 
transmembrane and intracellular domains; therefore the mechanisms by which CD14 
mediates signaling are still not fully understood.48 CD16 belongs to the family of Fc receptors 
found in mice and humans on all cells of hematopoietic origin. It is also referred to as FcRIII. 
CD16 is a multichain receptor involved in phagocytosis by macrophages and PMN and 
specifically recognizes the heavy chain of IgG antibodies.49 Binding to both, CD14 and CD16 
leads to the activation of PMN accompanied by the release of granule proteins and both are 
part of secretory vesicles (Figure 1-3). 
Reactive oxygen species: Reactive oxygen species (ROS) include compounds generated by 
incomplete oxygen reduction, such as superoxide anion (O2–), hydrogen peroxide (H2O2) and 
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thehydroxyl radical (HO•). ROS are crucial for antimicrobial activity, function as signaling 
molecules, but can also damage host tissue. They are not present in neutrophilic granules but 
do form in phagolysosoms and can be released by PMN.50-52 
 
1.2.2 PLASMACYTOID DENDRITIC CELLS 
DCs are professional antigen presenting cells equipped with high phagocytic activity, which 
take up, process and present antigen to T cells. However, they are a very heterogeneous cell 
population with various subtypes differing in location, migratory pathways and detailed 
immunological functions.53,54 In addition, DCs can rise from CLPs and CMPs, which is a 
unique feature among cells of haematopoietic origin (Figure 1-1).55 
One subpopulation of DCs are plasmacytoid dendritic cells (pDCs), which have first been 
described by Lennert und Remmele in 195856, but were for a long time referred to as 
plasmacytoid T cells or plasmacytoid monocytes in humans.57,58 Not until the late nineties of 
the last century it was agreed that this cell population carries dendritic cell characteristics and 
is identical with a cell population which had been termed “natural type I interferon-producing 
cell” (IPC).58-61 This conclusion promptly led to the identification of a pDC counterpart in 
mouse.62-64 In contrast to other DC populations pDC development is influenced by 
transcription factors (Spi-B65, ID2 and ID366) only known to be important for lymphocyte 
formation. In addition pDCs exhibit immunoglobulin H diversity-joining gene rearrangements 
and expression of markers typical for immature B- and T-cells.67 These findings together with 
their lymphoblast-like appearance under steady state conditions (Figure 1-4 a,b) made their 
lymphoid origin most likely, but was broadened by the finding that pDCs can rise from CLPs 
and CMPs (Figure 1).55 Other very recent studies may even support evidence for a distinct 
developmental pathway just for pDCs.68-71 PDCs fully evolve within the bone marrow and 
migrate to lymph nodes, mucosal-associated lymphoid tissues and spleen under steady state 
conditions with an average turnover of about 2 weeks.72 Migration is mediated through the 
expression of L-Selectin, CXCR4 and ChemR23 in response to their corresponding ligands 
CD34, SDF-1 (CXCL12) and chemerin. Under inflammatory conditions this repertoire is 
expanded by the expression of CXCR3 (ligands CXCL9/10/11), CCR5 (ligands CCL3/4/5) and 
CCR7 (ligands CCL19/CCL21). Among the latter chemerin seems to be the most specific and 
important regulator of pDC trafficking, especially under inflammatory conditions.73,74 Notably, 
in contrast to cDCs pDCs have the ability to enter lymphnodes via high endothelial venules 
(HEV), but do seldomly traffic by afferent lymphatics.75 One hallmark of DCs is antigen 
presentation, yet pDCs are less efficient compared to cDCs in presenting exogenous 
antigens58, but they are fully capable of presenting endogenous antigens and most likely are 
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as well able to cross present viral antigens76,77. One reason accounting for the weaker 
presentation of exogenous antigen by pDCs is their inability to accumulate long-lived MHCII-
peptide complexes on their cell surface, owing to a different regulation of the master 
transcription factor of the MHCII presentation machinery, CIITA (MHC class II 
transactivator).78 
 
 
 
Figure 1-4. Morphology of pDCs. (a) By electron microscopy, pDCs appear as lymphoblasts with a 
medium-to-large diameter, a slightly eccentric, indented, round or oval nucleus, lightly stained 
perinuclear areas and well developed rough endoplasmic reticulum. (b, c) By scanning electron 
microscopy, resting pDCs have a spherical shape (b), whereas CD40L-activated pDCs have a dendritic 
cell–like morphology (c). Original magnifications, ×7,000 (a) and ×3,000 (b,c) (adapted from Colonna et 
al.).
79
 
 
Although pDCs are a rare subtype in human and mouse they are the main source of type I 
interferons (IFN), producing up to 1000-fold higher levels of IFNs in comparison to other 
cells.59,80 Hence, during infection pDC numbers increase and can be detected in various 
tissues, such as lung, vaginal mucosa and skin.81 Furthermore, pDCs are described in the 
context of many autoinflammatory diseases, e.g. psoriasis82, systemic lupus erythematosus83 
and multiple sclerosis84. Human pDC markers are IL-3 receptor-a chain (CD123)58 and blood 
DC antigen 2 and 4 (BDCA-2 and BDCA-4)85, while mouse pDCs can be identified by sialic-
acid-binding immunoglobulin-like lectin H (SiglecH) expression86 and an antibody named 
mouse pDC antigen 1 (mPDCA-1)87. 
 
1.2.2.1 THE TYPE I INTERFERON RESPONSE 
pDCs are highly specialized for sensing viral and certain microbial infections, which is based 
on their selective expression of TLR7 and TLR9 and their capacity to respond to inactivated 
viral nucleic acids in the absence of viral replication.88 Upon activation of TLR7 and TLR9 the 
unique ability of pDCs to produce large amounts of type I IFNs is induced.89 TLRs are the best 
known PRRs comprising a family of conserved membrane-spanning molecules that contain an 
ectodomain of leucin-rich repeats, transmembrane domains and intracellular Toll–interleukin 1 
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(IL-1) receptor (TIR) domains. TLR7 and TLR9 are solely expressed intracellularly within the 
endoplasmatic reticulum (ER), endosomes, multivesicular bodies and lysosomes, but their 
activation seems to be restricted to acidified endolysosomal compartments.90 The ligand for 
TLR7 is viral single stranded RNA (ssRNA)91,92, instead TLR9 recognizes Cytidine-phosphate-
Guanosine (CpG)-rich bacterial (or viral) DNA93. In addition both receptors can also be 
activated by synthetic agonists, e.g. imidazoqinoline derivates (TLR7) or synthetic 
oligonucleotides (TLR9). Recognition of nucleic acids through these receptors leads to 
initiation of a signaling cascade involving a MyD88-IRAK4-TRAF6-complex that binds to IRF7, 
the master regulator of type I IFN responses in pDCs or other signaling molecules (Figure 1-
5). To provide sufficient IFN production, IRF7 is constitutively expressed by pDCs ensuring a 
constant and rapid assembly of the signaling described.94,95 In addition, pDCs are able to 
retain DNA in early endosomes for prolonged time periods potentially by multimeric DNA 
complex formation allowing a sustained activation of IRF7.96 In contrast, monomeric DNA 
quickly traffics through early endosomes into more acidic late endosomes initiating a different 
signaling cascade and therefore a different immune response of the cell.97 Thus, different 
pathogens may induce distinct answers, depending on which mechanism fits their killing best. 
IFNs per se are widely expressed cytokines that have potent antiviral and growth-inhibitory 
activity. The IFN family includes two main classes of related cytokines: type I IFNs and type II 
IFNs, which are named after their ability to 'interfere' with viral infections. Type I IFNs are 
numerous and all share obvious structural homology and bind to a common receptor (IFN 
receptor I). Instead, there is only one type II IFN – IFN – with its own receptor and no 
considerable structural homology with type I IFNs.98 Among the type I IFNs expressed by 
pDCs are IFN, IFN, IFNand IFN, hence the quantity of IFN is much higher relative to all 
other IFNs produced.99 Notably IFN influences several immune responses, e.g. maturation of 
CD11c+ conventional DCs100, induction of Th1 differentiation101, or stimulation of B cells to 
differentiate into antibody secreting plasma cells102.  
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Figure 1-5. TLR7 and TLR9-MyD88 signalling pathway 
Resting pDCs predominantly express TLR7 and TLR9, which reside in the endoplasmic reticulum (ER) 
in association with UNC93B and gp96. Following exposure to virus or nucleic acids, TLR7 and TLR9 
relocate from the ER to the endosomes to engage with their RNA or DNA agonists. Conformational 
changes in the TLRs lead to the activation of MyD88 (myeloid differentiation primary-response gene 88) 
in the cytosol. MyD88 in turn associates with a signal complex comprised of TRAF6 (tumor-necrosis 
factor (TNF)-receptor-associated factor 6), BTK (Bruton's tyrosine kinase), IRAK4 (interleukin-1-
receptor (IL-1R)-associated kinase 4) and IRAK1, which leads to the activation of IRF7 (interferon-
regulatory factor 7), NF- B (nuclear factor- B) and MAPKs (mitogen-activated protein kinases). 
Multimeric DNA binding to TLR9 occurs in the early endosomes, prolonged TLR9 signaling from the 
early endosome activates MyD88 and importantly IRF7, which promotes strong type I interferon (such 
as IFN , IFN , IFN  and IFN ) production. By contrast, monomeric DNA that binds to the TLR9 
complex quickly traffics through the early endosomes and into the more acidic late endosome or 
lysosome. This presumably activates a different set of signal mediators, particularly NF- B, MAPKs and 
IRF5, and thereby leads to production of e.g. IL-6 and TNF and upregulation of costimulatory molecules 
by pDC, without high levels of IFN production (modified from Gilliet et al.).
97
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1.2.2.2 PLASMACYTOID DENDRITIC CELLS IN AUTOIMMUNITY 
A pDC‟s main task is to sense for nucleic acids of foreign origin without responding to self-
nucleic acids of dying host cells. As a critical consequence the expression of TLR7 and TLR9 
is restricted to endosomal compartments within a cell, which has been shown to prevent 
recognition of self nucleic acids, but is not needed for ligand-receptor interactions.103 However, 
as already pointed out (1.2.2) pDCs are known to be involved in the pathophysiology of 
several autoimmune diseases. In patients with systemic lupus erythematosus (SLE) 
breakdown of innate tolerance occurs through the continuous activation of pDCs by circulating 
immune complexes, comprised of self DNA and antibodies to DNA or nucleoproteins.104,105 
These pDCs, in turn, permanently produce type I IFNs, which stimulate autoreactive B- and T-
cells.106,107 Mechanistically, complexes of self DNA and DNA-specific antibodies are bound 
and internalized by low-affinity Fc receptors for IgG (FcγRIIA) and translocated to TLR9-
containing endosomal compartments.108 Interestingly, this mechanism does not only account 
for pathophysiologic type I IFN levels, but also reduces therapeutic activity of 
glucocorticoids.109 Furthermore, in psoriasis, an autoimmune disease of the skin, free self-
DNA forms complexes with cationic LL-37, overexpressed and released by neutrophils as well 
as damaged epithelial cells.42 These complexes protect self-DNA from nuclease degradation 
and enter endosomal compartments of pDCs most likely via lipid rafts.110 Aggregated self-
DNA-LL37 complexes are retained within early endosomes and induce robust type I IFN 
production, as already described (1.2.2.1). In addition, high-mobility group box 1 protein 
(HMGB1), which is released by dying cells, may also ligate to nucleic acid-protein complexes. 
HMGB1 binds to RAGE (receptor for advanced glycation end-products) and thereby facilitates 
the association of DNA with TLR9 in early endosomes.111 
Of note, although being part of the discussion (ref. to 4.2.3), it may already be pointed out 
here, that both, SLE and psoriasis are associated with an increased risk of atherosclerosis 
(ref. to 1.3).112-114 Therefore, pathogenic mechanisms so far only accounting for one or the 
other may be important for all three and hence be transferred. 
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Figure 1-6. A model of pDCs sensing self-DNA. The antimicrobial peptide LL37 is secreted by 
damaged epithelial cells or deposited by tissue-infiltrating neutrophils. It binds self-DNA fragments 
released by dying cells to form aggregated and condensed structures that are protected from 
extracellular nuclease degradation and delivered via lipid rafts from the extracellular environment into 
the early endosomes of pDCs. Dying cells also release high-mobility group box 1 protein (HMGB1), 
which binds aggregated self-DNA–LL37 complexes and promotes their association with TLR9 in early 
endosomes by binding to RAGE (receptor for advanced glycation end-products). In SLE, DNA-specific 
IgG autoantibodies produced by autoreactive B cells bind self-DNA–LL37–HMGB1 complexes and 
potently increase their translocation into TLR9-containing endosomes in pDCs through FcRIIA. ITAM, 
immunoreceptor tyrosine-based activation motif (adapted from Gilliet et al.).
97
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1.2.3 OTHER CELLS 
As discussed before, immune responses depend very much on different cell types and their 
interaction. Thus, PMN and pDCs may be influenced by others, among which are monocytes, 
macrophages and T cells being described briefly in the following section. 
1.2.3.1 MONOCYTES 
Monocytes originate from bone marrow, where they do share early progenitors with 
granulocytes (Figure 1-1). Upon release of monocytes to the peripheral blood they circulate 
for several days until they enter various tissues to replenish macrophage populations. In 
human and mice monocytes make up to 5-10% of the total leukocyte population and vary in 
size and degree of granularity.115 They are fully equipped effector cells, exhibiting phagocytic 
activity, migration to sites of inflammation and production of inflammatory cytokines. Under 
inflammatory conditions monocytes rapidly differentiate to macrophages or inflammatory DCs 
depending on the surrounding milieu.53 In human blood, two subsets of monocytes are 
characterized by their differential expression ofCD14 and CD16: (i) “classical” CD14+CD16- 
monocytes, typically representing up to 95 % of peripheral monocytes in a healthy individual 
and (ii) “non-classical” CD14loCD16+ monocytes. These subsets differ phenotypically in their 
adhesion molecule and chemokine receptor expression.116 Mouse blood monocyte subtypes 
are identified by their expression of CD115, CD11band a different expression of granulocyte 
antigen 1 (Gr1). Mouse monocytes with a high Gr1 expression are also referred to as 
“inflammatory” monocytes, because of their rapid recruitment to sites of inflammation. Instead 
monocytes exhibiting a low surface expression of Gr1 are called “resident” monocytes, due to 
their prolonged persistence in blood and normal tissue.117 
1.2.3.2 MACROPHAGES 
Macrophages were first described by the Russian biologist Elie Metchnikoff in 1882, who 
recognized the presence of highly mobile mononuclear phagocytes in invertebrates.118 They 
are derived from myeloid progenitor cells, which ultimately develop into monocytes that enter 
the peripheral bloodstream. Circulating monocytes give rise to a variety of heterogeneous 
tissue-resident macrophages throughout the body, which have an important role in the 
maintenance of tissue homeostasis by clearance of dead cells and tissue repair after 
inflammation.115 Thus, macrophages are professional phagocytes expressing a variety of 
PRRs, such as the mannose receptor, TLRs and scavenger receptors. Additionally, 
macrophages are capable to function as an APC including the expression of MHCII and 
costimulatory molecules to activate an adaptive immune response.119 Macrophage activation 
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is thought to underlie two basic mechanisms resulting in two main phenotypes: “Classical” 
macrophages or M1 macrophages are activated through TLRs and IFN resulting in enhanced 
killing of intracellular pathogens, secretion of high levels of cytokines (e.g.interleukin (IL)12, IL-
23, IL-6 and TNF) and higher expression of costimulatory molecules. Instead, “alternative” or 
M2 macrophages differentiate in the presence of IL-4, IL-13, IL-1 or vitamin D3 leading to 
secretion of IL-10 and the expression of arginase-1 and the mannose receptor CD206.120-122 
1.2.3.3 T CELLS 
T cells are a large group of lymphocytes, originating from one progenitor (Figure 1-1) and are 
part of the adaptive immune response. They mature in the thymus (therefore called T cells) 
and can be divided into two main groups in mice and human based on their surface 
expression of CD4 and CD8. CD4+ T cells carry out “helper” functions and naïve CD4+ T cells 
differentiate into at least four types of T helper (Th) cells: Th1, Th2, Th17 and regulatory T 
cells (Treg).123,124 Th1 cells mediate a cellular immune response while Th2 cells trigger a 
humoral response. Instead, Th17 cells appear to play an integral role in both tissue 
inflammation and activation of neutrophils to combat extracellular bacteria. Th1, Th2 and Th17 
immune responses influence each other antagonistically and at a time one is dominating a 
certain pathogen response.125 CD8+ T cells are called cytotoxic T cells, because of their ability 
to kill virus-infected and tumor cells. In general both, CD4+ and CD8+ T cell populations carry 
T cell antigen receptor (TCR)/CD3 complexes and are able to “mature” in the presence of an 
antigen. CD4+ T cells respond to antigens presented by APCs via MHCII, CD8+ T cells 
recognize their targets by MHCI.123,126 
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1.3 ATHEROSCLEROSIS 
Atherosclerosis, the term has its etymologically roots in the two Greek words „athera‟ (gruel) 
and „sklerosis‟ (induration), is now agreed to be a chronic inflammatory disease of the vessel 
wall driven by intense immunological activity, of both, innate and adaptive immunity. Moreover 
atherosclerosis is the most common pathophysiological process leading to CAD and therefore 
heads the list of death causes in developed countries.1,127 
Already more than a 180 years ago, in 1829, Jean Lobstein implemented the term 
„atherosclerosis‟ followed by his two colleagues Carl von Rokitansky and Rudolf Virchow, who 
proposed two opposing views on the pathology of atherosclerosis in the middle of the 19th 
century. Rokitansky assumed that initial injury of the vessel wall due to mechanical trauma led 
to endothelial dysfunction, whereas Virchow already postulated the critical role of 
inflammatory cells in the pathology of atherosclerosis.128 In the early years of the 20th century 
the correlation of high cholesterol levels in disease progression could be elucidated129,130, 
however, detailed insight in the pathogenic mechanisms remained elusive. An extended view 
of the Rokitansky proposal was established by Ross, who came up with the “response to 
injury” hypothesis in the 1970ties.131-133 This hypothesis was further broadened in the nineties 
by Steinberg and others, who suggested altered lipoproteins as the initial triggers of the 
disease, primarily oxidized low-density lipoprotein (oxLDL).134-136 
But, even to date – despite the intensive research in this field, the concordant acceptance of 
hyperlipidemia as the main risk factor and growing evidence that atherogenesis is strongly 
regulated by immunological mechanisms – the initial reason unbalancing the system remains 
vague.127 
Pathomechanism: Atherosclerotic lesions, also termed plaques, originate from local 
endothelial dysfunctions under elevated levels of LDL. This leads to an infiltration of blood 
borne immune cells, mostly leukocytes and anasymmetrical thickening of the intima (most 
inner layer of the vessel) (Figure 1-7a). Intima swelling is accompanied by the recruitment of 
monocytes, which turn into lipid-laden macrophages, also known as foam cells. These early 
lesions, referred to as “fatty streaks”, are typical for younger individuals and asymptomatic, but 
can progress or disappear with time (Figure 1-7b). Continuous cell influx leads to plaque 
progression resulting in mature plaques (atheromas), which are more complex.  
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Figure 1-7. Development and progression of 
atherosclerosis:  
 
a) Endothelial-cell dysfunction and activation 
under pro-inflammatory conditions of hyper-
lipidemia leads to early platelet and leukocyte 
adhesion and increased permeability of the 
endothelium.  
 
 
 
 
 
 
b) Monocytes that are recruited to the intima 
and subintima accumulate lipids and transform 
into macrophages or foam cells, which make up 
fatty streaks. Continued mononuclear-cell 
influx, deposition of matrix components and 
recruitment of smooth muscle cells give rise to 
the fibroproliferative progression of the plaques.  
 
 
 
c) Apoptosis of macrophages and other plaque 
cells creates a necrotic core, and a fibrous cap 
that consists of matrix and a smooth-muscle-
cell layer forms. Neovascularization can occur 
within the plaque and from the adventitia, and 
leakage of fragile vessels can lead to plaque 
hemorrhage.  
 
 
 
 
 
 
 
 
 
d) Thinning and erosion of the fibrous cap in 
unstable plaques, for example, owing to matrix 
degradation by proteases, ultimately results in 
plaque rupture, with release of debris, 
activation of the coagulation system and plaque 
thrombosis of the artery. This leads to arterial 
occlusion and myocardial infarction or stroke 
(modified from Weber et al.).
137
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Atheromas consist of a necrotic core (containing lipids), surrounded by foam cells and other 
immune cells overall covered by a cap of smooth muscle cells and collagen rich matrix (Figure 
1-7c). Finally the release of pro-inflammatory cytokines and proteases reduces collagen 
formation and thins the collagenous cap, which leads to plaque weakening and may peak in 
plaque rupture (Figure 1-7d). Rupture results in thrombus formation possibly causing acute 
ischemia, manifesting as myocardial infarction or stroke.1,127,135,137-139 
 
1.3.1 NEUTROPHILS IN ATHEROSCLEROSIS 
Although atherosclerosis is a chronic inflammatory disease and neutrophils are thought to be 
more important for acute and early inflammatory responses, growing evidence underlines their 
impact in the onset of atherosclerosis.39,140,141 One reason for their underestimation in 
atherosclerotic lesions formation so far is most likely due to only low numbers being 
detectable in plaque regions. Yet, this may be explained by their short life span along with 
their high turnover. However PMN are detectable in both, human142 and mice141 lesions and a 
correlation of peripheral PMN counts with myocardial infarction in humans has already been 
shown.143,144 Additionally, as demonstrated in a murine model of atherosclerosis, neutrophil 
numbers in blood seem to positively correlate with plaque size, whereas depletion of PMN 
reduces plaque formation in these mice.141,145 
Hence, presumably several mechanisms may account for PMN in atherosclerosis overviewed 
in Figure 1-8. The broad variety of granule proteins released and deposited by PMN will most 
likely trigger monocytes adhesion and extravasation, finally leading to foam cell formation.39 In 
addition macrophages will be activated by these granule constituents and subsequently 
release proinflammatory cytokines.146 Furthermore, apoptotic neutrophils eaten up by 
macrophages might eventually overload the phagocytic capacity of these macrophages, 
resulting in secondary necrosis and therefore increased inflammation within the lesion.147 
Ultimately, ROS formation and subsequent modification of LDL to oxLDL together with the 
proteolytic weakening of the fibrous cap by PMN-derived proteases may exacerbate plaque 
destabilization.148 In summary, PMN are clearly involved in the pathogenesis of 
atherosclerosis, but the assumptions made on their contributions to this disease have to be 
further investigated. 
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Figure 1-8. Potential role of PMN in atherosclerosis. Although direct proof only exists for the 
correlation of peripheral PMN count and plaque size, the PMN may be involved in several critical 
processes in atherosclerosis. Deposition of PMN granule proteins on the endothelium and in the vessel 
wall may trigger monocyte adhesion and extravasation. There granule components enhance 
macrophage differentiation and activity resulting in release of pro-inflammatory cytokines. Extravasated 
LDL may be trapped by binding of PMN-derived HNPs and further modified via ROS, thereby supplying 
substrate for foam cell development. Proteases released from PMN granules may further weaken the 
fibrous cap and promote plaque rupture. In addition, MPO reduces the bioavailability of NO and leads to 
production of HOCl. The latter may induce endothelial cell apoptosis and desquamation, thus resulting 
in plaque erosion (adapted from Soehnlein and Weber).
148
 
 
 
1.3.2 PLASMACYTOID DENDRITIC CELLS IN ATHEROSCLEROSIS 
Both, cDCs and pDCs are found in atherosclerotic lesions in human149 and mice150. However, 
since the first description of DCs within the intima of arteries151 and in atherosclerotic 
lesions152 in 1995 the function of DCs within healthy and atherosclerosis-prone arteries needs 
to be further investigated.127,141 PDCs are described in the shoulder region of the plaque, 
where they cluster with cDCs and most likely produce type I IFNs in response to nucleic acids 
of self and foreign origin.  
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Figure 1-9. Potential role of dendritic cells in the atherosclerotic plaque. Activated cDC and 
macrophages produce effector molecules such as metalloproteinases degrading the extracellular 
matrix. Further, they trigger the recruitment of cytotoxic T cells via production of IL-12. PDC are mainly 
activated by viral antigens binding tointracellular receptors such as TLR7 and TLR9. Activated pDC 
produce vast amounts of IFN-α. This cytokine enhances the sensitivity of other antigen presenting cells 
by upregulation of TLR4. Furthermore, it upregulates the expression of the pro-apoptotic molecule 
TRAIL on T cells thereby multiplying their cytotoxic potential. These TRAIL-expressing T cells have the 
ability to kill plaque-resident cells such as activated VSMC and EC expressing the death receptor DR5. 
Abbreviations: EC, endothelial cells, DR5, death receptor 5, TNF-α, tumor necrosis factor-alpha 
(modified from Niessner et al.).
153
 
 
Secretion of IFNα seems to correlate with plaque instability, activating CD4+ T cells, which in 
turn produce IFNγ and TRAIL (TNF-related apoptosis inducing ligand) in an antigen 
independent manner leading to apoptosis of vascular smooth muscle cells.154 In addition IFNα 
may function as an inflammatory amplifier inducing upregulation of TLR4 on cDCs, resulting in 
a synergistic effect of different danger signals within the two DC subsets.155 Another very 
recent study demonstrates that IFN enhances macrophage-endothelial cell adhesion and 
promotes leukocyte attraction to atherosclerosis-prone sites as well as increased macrophage 
accumulation within the plaque.156 In contrast, human and mouse pDC do both have the ability 
to trigger the development of regulatory T cell responses, e.g. inhibiting acute graft-versus 
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host disease157 or mediating tolerance to vascularized grafts158. Thus, our understanding of 
how dendritic cells, including pDCs, assign to certain stages of atherosclerosis needs to be 
further improved, also with regard to clinical applications.153 
 
1.4 AIM OF THE STUDY 
One of the pressing goals of atherosclerosis research is to understand the participation of the 
immune system in the pathomechanisms leading to plaque formation and progression. Major 
aim of this thesis was the systematically examination of the contribution of pDCs and PMN to 
atherosclerotic lesion formation. 
 
PMN were long underestimated in atherosclerotic lesions formation most likely due to their low 
numbers in plaque regions and their importance in acute inflammation. However, PMN have 
recently been implicated in lesion development and an increase of circulating neutrophils 
positively correlates with plaque sizes. This study aims at the understanding to which extend 
this contribution influences plaque formation. 
 How does atherosclerosis develop in a mouse model with impaired macrophage 
functions, but increased PMN numbers?  
 How far may lesion progression be driven by PMN exclusively? 
 Is a myeloproliferative disorder a risk factor in atherosclerosis? 
 
The role of pDCs in atherosclerosis is only poorly understood and studies shading light on this 
issue are very scarce. Therefore, detailed analysis of how pDCs influence atherosclerosis per 
se is outlined here. 
 Does pDC activation or depletion influence disease development? 
 Is pDC activity influenced by classical risk factors (e.g. oxLDL)? 
 Does the implication of pDCs in the pathomechanisms of various autoimmune diseases 
suggest similar activation patterns in atherosclerosis?  
 
 
 
  2 MATERIALS AND METHODS 
 
 21 
2 MATERIALS AND METHODS 
Protocols were adapted from standard protocols159 if not stated otherwise. All solutions were 
prepared with double distilled water (Heraeus Destamat, Heraeus, Germany) or Millipore 
water (Milli-Q Plus ultrapure purification, Millipore,MA). Reagents were from Fluka (Buchs, 
Switzerland), Sigma-Aldrich (Deisenhofen, Germany), or Roth (Karlsruhe, Germany), if not 
stated otherwise. 
2.1 GENERAL EQUIPMENT 
equipment source 
autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
balance Analytical Plus, (Ohaus, Pine Brook, NJ, USA) 
centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), 
Heraeus Labofuge 400 and Heraeus Multifuge 3 S-R 
(Heraeus, Osterode,Germany) 
flow cytometers FACSCantoII, FACSAria (BD Biosciences, San 
Jose, CA, USA) 
fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
gel electrophoresis Mini-sub cell GT (Bio-Rad, Hercules, CA, USA) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
microscopes Olympus IX71 and BX51 (Olympus 
Optical,Hamburg,Germany), Leica DMLB (Leica, 
Wetzlar, Germany) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules, CA), DNA Engine 
Opticon (MJResearch, Hercules, CA, USA) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
spectrometer NanoDrop (Peqlab, Erlangen, Germany) 
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2.2 MICE 
Wild-type (wt) C57BL/6, Apolipoprotein E deficient (Apoe-/-)160,161 and low-density lipoprotein 
receptor (LDLR)-deficient mice (Ldlr-/-)162 were obtained from the local animal breeding facility 
or purchased at Charles River, England or Janvier, Belgium. Apoe-/- and Ldlr-/- mice are 
established mouse models to study the development and disease progression of 
atherosclerosis.  
OT-II163 transgenic mice, interferon regulatory factor 8 (formerly known as interferon 
consensus sequence binding protein, ICSBP) knock out mice (Irf8-/-)164 and the cathelin-
related antimicrobial peptide (CRAMP) knock out mice (Cramp-/-), encoded by the gene Cnlp 
(Camp cathelicidin antimicrobial peptide)165, were obtained from the local animal breeding 
facility (University Hospital, Aachen Germany).  
OT-II mice express a mouse -chain and -chain TCR that pairs with the CD4 co-receptor and 
is specific for chicken ovalbumin 323-339 (OVA-2) presented by MHC class II molecules. 
CD4+T cells isolated from these mice exhibit a dose-dependent proliferation in response to 
OVA-2 peptide. Irf8-/- mice have two prominent phenotypes: first is enhanced susceptibility to 
viral infections and second is a deregulated hematopoiesis manifesting in a syndrome similar 
to human chronic myeloid leukemia. Cramp-/- mice demonstrated no obvious phenotype when 
housed under aseptic conditions, but are more susceptible to infections of Group A 
Streptococcus. 
2.3 CYTOKINES AND RECOMBINANT PROTEINS 
name source 
Chemerin R&D systems (Minneapolis, MN USA ) 
CRAMP Innovagen (Lund, Schweden) 
murine FLT3-ligand PeproTech (Rocky Hill, NJ, USA) 
murine Interferon alpha PBL laboratories, Piscataway, USA 
murine Interferon alpha HyCult Biotec, Uden, Netherlands 
OVA-2 (323-339) AnaSpec (San Jose, CA, USA) 
Platelet activating factor Enzo, Life sciences (Plymouth Meeting, USA) 
murine TNFα PeproTech 
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2.4 MISCELLANEOUS REAGENTS 
(Di†)-oxidized LDL         Intracel (Frederick, MD, USA) 
Calcein (cell permeant dye)      Invitrogen (Carlsbad, CA, USA) 
Dexamethasone (synthetic glucocorticoid) Sigma-Aldrich 
Annexin V (molecular probe)      BD Biosciences 
2.5 TOLL LIKE RECEPTOR STIMULI 
CpG ODNs are synthetic oligonucleotides (ODN) that contain unmethylated CpG 
dinucleotides (CpG motifs).166 CpG ODNs are recognized by TLR9 leading to strong 
immunostimulatory effects.167 Among the stimulatory CpG ODNs three different types have 
been described: types A, B and C. These three differ in their immune stimulatory activities. 
Type A CpG ODNs induce high IFN-α production from pDCs, but are weak stimulators of 
TLR9-dependent NF-κB signaling. Type B CpG ODNs strongly activate B cells but stimulate 
weakly IFN-α secretion by pDCs. Type C CpG ODNs combine features of both types.168 All 
CpG types will finally induce pDC maturation resulting in an upregulation of costimulatory 
molecules and the ability to function as an antigen presenting dendritic cell. ODN 1585169 
(Type A) was used for in vitro and in vivo stimulation of pDCs (2.8.3) and was purchased from 
InvivoGen (San Diego, CA, USA). 
 
                                               
† 1,1`-dioctadecyl-3,3,3`,3`-tetramethylindocarbo-cyanineperchlorate   
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2.4 ANTIBODIES 
2.4.1 PRIMARY ANTIBODIES 
Name mAb clone source 
anti-SMA mouse anti-human 1A4 Dako, Glostrup, Denmark 
MOMA-2 rat anti-mouse MCA519 AbD Serotec, Düsseldorf, 
Germany 
CD3 mouse anti-human PC3/188A Santa-Cruz Biotechnology, 
Santa Cruz, CA, USA 
Ly6G rat anti-mouse 1A8 BD Biosciences, San Jose, 
CA, USA 
SiglecH  rat anti-mouse 440c eBioscience, San Diego,CA, 
USA 
Cramp rabbit anti mouse  Innovagen 
IgG  rabbit anti mouse  Vector Laboratories 
Myeloperoxidase rat anti-mouse RB-373-AO Neomarkers Fremont, CA, 
USA 
MMP9 rat anti-mouse M17 Santa Cruz Biotechnology 
 
2.4.2 DIRECTLY CONJUGATED ANTIBODIES 
name mAB clone source 
B220-PE-Cy7 rat anti-mouse RA3-6B2 eBioscience 
CD115-PE rat anti-mouse AFS98 eBioscience 
CD11b-PerCP rat anti-mouse M1/70 BD Pharmingen 
CD11c-PE-Cy7 rat anti-mouse N418, eBioscience 
CD14-PE-Cy7 rat anti-mouse Sa14-2 BioLegend, San Diego, CA,USA 
CD16-PE rat anti-mouse 93 BioLegend 
CD19-PerCP rat anti-mouse RA3-6B2 eBioscience 
CD25-APC or PE rat anti-mouse PC61.5 eBioscience 
CD36 rat anti-mouse No.72-1  eBioscience 
CD3-PerCP,APC,FITC rat anti-mouse 145-2C11 eBioscience 
CD40-APC rat anti-mouse 1C10 eBioscience 
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name mAB clone source 
CD45-APC-Cy7 rat anti-mouse 30-F11 BD Pharmingen 
CD4-PE,APC, FITC rat anti-mouse RM4-5 eBioscience 
CD80-APC rat anti-mouse 16-10A1 eBioscience 
CD86-PE rat anti-mouse GL1 eBioscience 
CD8a-PE or PE-Cy7 rat anti-mouse 53-6.7 eBioscience 
F4/80-APC rat anti-mouse A3-1 Serotec, Raleigh, NC, USA 
FoxP3-APC rat anti-mouse FJK-16s  eBioscience 
Gr-1-PerCP rat anti-mouse RB6-8C5 BD Pharmingen 
Ly6G-APC rat anti-mouse 1A8 BioLegend 
MHC-II-APC rat anti-mouse M5/114.15.2 BioLegend 
MHC-II-PE rat anti-mouse 2G9 BD Pharmingen 
PDCA-1-PE rat anti-mouse JF05-1C2.4.1 Miltenyi Biotec 
SiglecH-APC rat anti-mouse eBio440c eBioscience 
 
2.4.3 SECONDARY ANTIBODIES 
name AB source 
Rat IgG,Cy3-conjugated donkey-anti-rat-IgG Jackson ImmunoResearch, 
West Grove, PA 
Mouse IgG, Cy3 
conjugated 
donkey-anti-mouse-IgG Santa-Cruz Biotechnology 
 
2.4.4 DEPLETION ANTIBODIES 
name mAB clone source 
PDCA-1 rat anti-mouse purified JF05-1C2.4.1 Miltenyi Biotec 
Ly-6G rat anti-mouse purified RB6-8C5 BioXCell, West Lebanon, NH 
Isotype control rat IgG2b, purified LTF-2 BioXCell 
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2.5 CELL CULTURE 
Cell culture was performed under sterile conditions in a laminar flowhood. Cells were 
maintained in a CO2-incubator at 37°C and a humidified 5% CO2 atmosphere. Cells were 
cultured in growth medium (RPMI 1640) supplemented with 10% (v/v) fetal calf serum (FCS), 
2 mM L-glutamine and penicillin (100 U/mL)/streptomycin (100 μg/mL) (PAA, Pasching, 
Austria) to avoid contamination with bacteria. FCS was incubated at 56°C for 30 min to 
inactivate the complement system and stored at -20°C until use. All media and solutions used 
for cell culture were from Gibco if not stated otherwise and purchased sterile or sterilized 
through a 0.2 μm filter. Cultured cells were regularly tested to be mycoplasma free by the 
VenorGeM Mycoplasma detection kit (Minerva Biolabs, Berlin, Germany). 
 
2.5.1 PREPARATION OF PRIMARY CELL SUSPENSIONS 
For flow cytometric analysis of lymph nodes (brachial, axillary, cervical, popliteal, and inguinal) 
or spleen organs were digested with collagenase D free of tryptic activity (Sigma-Aldrich) for 
30 min at 37°C. Cells isolated from spleen were lysed with red blood cell lysis buffer for 5 min. 
Single cell suspensions were generated by pressing lymph nodes (LN) or spleen cells through 
a 70-μM cell strainer. Aortas were excised and digested with 1.8 mg/ml of LPS-free 
Blendzyme Liberase III (Roche, Mannheim, Germany) diluted 1:20 in RPMI 1640 for 30 min at 
37°C. Hanks`complete solution was added, and cells were passed through a 70-μm strainer. 
Bone marrow (BM) cells were extracted from the tibia and femur with Hank‟s complete 
solution using a 1 ml syringe and 23-gauge needle. The single cell suspension was 
centrifuged and the pellet resuspended in about 1 ml RBC lysis buffer for 5 min. Cells were 
washed 2-3 times and passed through a cell strainer to remove bone fragments and dead cell 
clumps. Whole blood obtained from the retro-orbital plexus of mice was EDTA-buffered and 
subjected to red-cell lysis for 15 min followed by 2 wash steps in Hank‟s complete solution. 
Cells were then used for further analysis. 
______________________________ 
Red blood cell lysis buffer: 
0.8 % ammonium chloride, 10 mM potassium hydrogen carbonate (KHCO3), 0.1 mM 
EDTA, pH 8.0 
Hanks´complete solution: 
1 x HBSS, 0.1% BSA and 0.3 mM EDTA 
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2.5.2 ISOLATION OF DCS 
PDCs were isolated from spleens of wt mice via depletion of all other cells. For this purpose, 
the Plasmacytoid Dendritic cell Isolation Kit II (containinga cocktail of biotin-conjugated 
antibodies as well as anti-biotin MicroBeads) and a separation column (all Miltenyi Biotec, 
Bergisch-Gladbach, Germany) were used according to the recommended protocol, allowing a 
negative selection of pDCs. Briefly, the freshly isolated spleen cells were mixed with the 
cocktail of biotin-conjugated antibodies (Abs) and incubated for 10 min at 4°C. After washing 
with MACSbuffer, the cells were mixed with magnetic anti-biotin microbeads, incubated for 15 
min at 4°C, washed and loaded onto the separation column. The magnetically labeled cells 
were retained in a separation column placed in a magnetic field, whereas cells were 
recovered in the eluat and cultured in cell culture medium (2.5) for further analysis.  
For the isolation of CD11c+ DCs cells from spleens and LN of wt mice cell suspensions were 
incubated with CD11c Micro Beads (Miltenyi) for 15 min at 4°C, washed and loaded onto the 
separation column. The CD11c+ DCs retained in the separation column and could be eluted 
after the column was removed from the magnetic field. Further analyses were performed in 
culture medium (2.5). 
 
2.5.3 ISOLATION OF CD4+ T CELLS 
CD4+T cells were isolated from secondary lymphoid organs of OT-II mice via depletion of non-
CD4+T cells. For this purpose, the CD4+T cell Isolation Kit (containing a cocktail of biotin-
conjugated Abs against CD8a, CD45R, CD11b, CD49b and Ter-119, as well as magnetic anti-
biotin MicroBeads) and a separation column (all Miltenyi Biotec) were used according to the 
recommended protocol, allowing a negative selection of CD4+T cells. The isolation procedure 
is identical to the one already described for the isolation of pDCs (2.5.1). 
______________________ 
MACS buffer: 
PBS, 0.5 % BSA, 2 mM EDTA 
 
2.5.4CELL SORTING 
PDCs: For isolation of pDCs via cell sorting freshly isolated spleen or BM cells of wt mice 
were mixed with Abs against CD45, B220 (CD45RA) and SiglecH (440c). Neutrophils: For 
isolation of neutrophils via cell sorting freshly isolated blood, bone marrow or air pouch lavage 
cells were mixed with an Ab cocktail against CD45, Gr1 and Ly6-G. Cells were sorted with a 
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BD FACSAria (BD Bioscience), and used in RT-PCR, phagocytosis, migration, proliferation 
and apoptosis assays. 
 
2.5.5 BLOOD SMEAR STAINING AND LIPID ANALYSIS 
Mouse peripheral blood smears were prepared and analyzed in the local animal facility 
(University Hospital, Aachen, Germany). All slights were Wright‟s stained. This staining 
enables the discrimination between different types of „white‟ blood cells, such as neutrophils, 
lymphocytes, monocytes, eosinophils and basophiles as well as platelets. 
Cholesterol and triglyceride levels were determined by routine laboratory assays (Department 
of Clinical Chemistry, University Hospital Aachen). 
2.6 MOLECULAR METHODS 
2.6.1 ISOLATION OF DNA 
Genomic DNA for mouse genotyping was isolated from mouse tail cuts with the Bio Sprinter 
96 from Qiagen (Hilden, Germany) according to the manufacturer‟s protocol. 
 
2.6.2 ISOLATION OF RNA 
Dependent on cell number, RNA from sorted peripheral cells (2.5.4), aortas or whole lymph 
nodes and spleens were isolated using either the RNeasy Mini Kit or the RNeasy Micro Kit 
(both Qiagen, Hilden, Germany) or the ZR RNA MicroPrep RNA isolation kit (Zymo Research) 
according to manufacturer‟s protocols. Isolation was followed by digestion of genomic DNA 
using the RNase-free DNase set (Qiagen, Hilden, Germany) according to the manufacturer‟s 
protocol. 
 
2.6.3 QUANTIFICATION OF DNA AND RNA 
DNA and RNA concentrations and purity were determined by measuring the absorbance at 
260 nm (A260) and 280nm (A280) in a spectrophotometer (Nanodrop). Pure DNA or RNA has an 
A260/A280ratio of 1.8-2.0 at pH 7.0. 
 
2.6.2 QUANTATIVE REAL-TIME POLYMERASE CHAIN REACTION (PCR) 
To determine the gene expression of SiglecH (a specific pDC marker), the cytokine IFN and 
the antimicrobial peptide Cramp a real-time PCR was performed using the SYBR Advantage 
qPCR Kit (Clontech, Saint-Germain-en-Laye, France) and gene specific primers according to 
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manufacturer‟s protocol. The real-time PCR technique is based on the specific fluorescence 
properties of SYBRGreen when bound to double stranded DNA, i.e. the increase in double-
stranded DNA can be directly detected. Thus, the increase of fluorescence over the reaction 
time can be associated with the initial mRNA concentration. After determination of the RNA 
amount (2.6.1), up to 1 μg total RNA was reverse-transcribed into cDNA with the M-MLV RT 
Kit (Promega, Madison, WI, USA) using oligo-dT or Random Hexamer primers (Sigma-
Aldrich) at 37°C for 1 h. 20 ng cDNA were assessed in each real-time PCR reaction. The 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
reference gene. 
 
Reverse transcription: 5 μl 5x reverse transcription buffer 
         0.5 μl dNTP mix (20 mM each) 
         1.1 μl 10 μM oligo-dT or Random Hexamer primer 
         1 μl reverse transcriptase enzyme 
         up to 2 μg template RNA 
         H2O to a final volume of 25 μl 
 
Real time-PCR :    2 μl cDNA or H2O 
         13 μl 2x QuantiTect SYBR Green PCR Master Mix 
         forward primer to a final concentration of 0.5 μM 
         reverse primer to a final concentration of 0.5 μM 
         RNase free water to final volume of 25 μl 
 
Real time-PCR Program:  
         1. Initial activation  95°C, 15 min 
         2. Denaturation   94°C, 15 sec 
         3. Annealing   58°C, 30 sec 
         4. Extension    72°C, 30 sec 
         5. Plate read 
 
The relative mRNA expression is calculated as follows: 
ΔCt = Ct(target gene) - Ct(reference gene); ΔΔCt = ΔCt(sample) - ΔCt(control sample) 
relative mRNA expression: ( Ct) 2 
−(ΔΔCt) 
Ct: Cycle number at which the fluorescence intensity exceeds a determined threshold 
 
 
 
X 45 cycles 
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Primers for real-time PCR: 
mouse Cramp:  for  5'-TCCCAAGTCTGTGAGGTTCC-3',  
       rev 5'- CCCATACACTGCTTCACCAC -3', 
 
mouse IFNα   for  5‟- TCTGATGCAGCAGGTGGG-3‟ 
       rev 5‟- AGGGCTCTCCAGACTTCTGCTCTG-3‟ 
 
mouse SiglecH:  for  5'- GCTGGGATGCTGCTGTCCCG-3', 
       rev 5'- GGTGGCAGGGCACAAGGACA -3';  
 
mouse Gapdh   for  5'-CCATCACCATCTTCCAGGAG-3' 
       rev 5'-GTGGTTCACACCCATCACAA-3' 
 
2.7 PROTEIN ASSAYS 
2.7.1 FLOW CYTOMETRY 
Flow cytometry can be used to analyze cells by their size, granularity and protein expression 
(by e.g. fluorescence-conjugated detection antibodies) or to sort cell populations (FACS, 
Fluorescent activated cell sorting). In a buffer stream, one cell at a time passes by an argon 
laser, which excites fluorescently labeled cells. Measurements of the size (forward scatter) 
and granularity (sideward scatter) are independent from the fluorescence signal. 
Measurement of fluorescence intensity using fluorescence-labeled antibodies was performed 
to examine and distinguish different cell populations in lymph nodes and spleen by the 
expression of different markers on the cell surface. In addition, the maturation status of pDCs 
was examined using Abs against costimulatory molecules, e.g. CD86. To determine the state 
of neutrophil activation CD11b and CD14 were used. All flow cytometry results were displayed 
as dot plots showing the logarithmic distribution of the fluorescence intensity or as diagrams 
demonstrating the change in mean fluorescence intensity (MFI) or percentage (%). For 
surface receptor expression determination, up to 1 × 106 cells were resuspended in FACS 
staining buffer with specific fluorescence-conjugated antibodies (1:100) and incubated for 20 
min on ice. The cells were washed with Hanks` complete and analyzed immediately in a 
FACS CantoII (BD Biosciences) and evaluated with FlowJo Software (Treestar, Inc, Ashland, 
OR, USA), if not stated otherwise. As control the fluorescence minus one (FMO) method was 
used. 
______________________ 
FACS staining buffer: 
PBS, 2 % BSA, 2 % mouse serum, 2 % rabbit serum, 2 % human serum 
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2.7.2 BEAD ARRAY 
Cell culture supernatants, mouse sera, air pouch and peritoneal lavage fluid were analyzed for 
various cytokines using flow cytomix Th1/Th2 10 plex assay (BenderMedSystems, Wien, 
Austria), sample preparation and analysis was performed according to the manufacturer‟s 
protocol.  
Principle: The kit allows the simultaneous detection and quantification of soluble murine GM-
CSF, IFN-γ, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL- 17 and TNF-αin a single sample. The 
bead-based assay follows the same principle as a sandwich immunoassay. Fluorescent 
polystyrol beads are coupled with antibodies specific to the analytes to be detected. Beads 
are differentiated by their sizes and distinct spectral signature by flow cytometry. Two sets of 
beads with different sizes (4 μm and 5 μm) are used in this assay. Each of the two sizes 
consists of bead populations which are differentiated by varying intensities of an internally 
fluorescent dye. The dye emits in the far red (690 nm), which is detected in the FL-3/FL-4 
channel. The combination of the two different bead sizes and different internal dye intensities 
makes it possible to distinguish up to 20 bead sets in one fluorescent channel. Streptavidin- 
phycoerythrin (PE), which binds to the biotin conjugate, emits at 578 nm and is detected in the 
FL-2 channel and allows the quantification of the analyte. For determination of cytokines 
released by OT-II T cells, a mix of coupled beads is incubated with the supernatants for 2 h at 
RT. During the incubation, analytes in the supernatants bind to the antibodies coupled to the 
beads. At the same time, a biotin-conjugated antibody mix is added, which binds to the 
analytes bound to the capture antibodies. Afterwards, streptavidin-PE is added for 1 h at RT. 
Samples were examined by FACS CantoII (BD Bioscience), the results were analyzed using 
the FlowCytomix Pro 2.2 analysis software. Standard curves based on the MFI of cytokine 
beads were used for quantifying sample cytokine concentrations. 
 
2.7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
ELISA is an immunological method to determine the amount of an antigen in biological fluids. 
All ELISAs performed were based on the principle of a sandwich immunoassay. Briefly, a 
purified Ab specific for the antigen of interest is pre-coated onto a microplate. All samples and 
standards are added, and any antigen present binds to the capture Ab. After washing the 
detecting Ab is added, and binds to the antigen. The next step is the addition of an enzyme-
linked secondary Ab, which binds to the detecting Ab. After adding the substrate the enzyme 
reaction yields a blue product that turns yellow when the stop solution is included. The 
intensity of the color measured is in proportion to the amount of antigen bound in the initial 
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step. The sample values are then read of a standard curve. Cell culture supernatants, mouse 
sera, air pouch or peritoneal lavage fluids were analyzed for one or more of the following 
targets: IFN(VeriKineTM Mouse Interferon-Alpha ELISA Kit, PBL laboratoriesIL-10 (Mouse 
IL-10 Quantikine ELISA Kit, R&D Systems), antinuclear antibodies (ANAs) (Mouse Anti-ANA 
Kit, Alpha Diagnostic, San Antonio, TX, USA) double stranded DNA (dsDNA) (Mouse anti-
dsDNA Kit, Alpha Diagnostic), Single stranded DNA (ssDNA) (mouse anti-ssDNA, Alpha 
Diagnostic), Chemerin (Mouse Chemerin Quantikine ELISA Kit, R&D Systems) or Flt3L 
(Mouse Flt3L Quantakine ELISA Kit, R&D Systems). 
 
2.7.4 ANALYSIS OF MPO AND MMP-9 ACTIVITY AND ROS FORMATION 
MPO activity within the air pouch lavage fluid was measured by spectrophotometry using 
enzyme-specific substrates as described.170 MMP-9 activity was quantified using the 
SensoLyte MMP-9 assay kit (Anaspec. Fremont, CA, USA), based on the proteolytic cleavage 
of a specific substrate. The fluorescent product was measured at 520 nm using a 
spectrophotometer. For the detection of ROS formation, neutrophils from Irf8+/+ or Irf8-/- mice 
were seeded in 96-well plates and loaded with 2′,7′-dichlorodihydrofluorescein diacetate 
(H2DCFDA, Invitrogen) in PBS at a final concentration of 10 μM for 30 min at 37°C. 
Fluorescence was measured before and every 4 minutes after exposure to TNFα (10 ng/ml), 
phorbol 12-myristate 13-acetate (PMA; 10 ng/ml), or vehicle (PBS) using a 
spectrophotometer.  
 
2.7.5 HISTOCHEMISTRY 
Hearts and aortas were harvested by in situ perfusion fixation with 4% Paraformaldeyd (PFA). 
The extent of atherosclerosis was assessed in aortic roots and on thoracoabdominal aortas by 
staining for lipid depositions with 0.5 % oil-red-O (Sigma-Aldrich) for 30 minutes. For roots 5 
μm transversal sections (3-6/mouse) were used. Aortas were opened longitudinally along the 
ventral midline, and lesion areas in en face preparation were stained. The percentage of lipid 
deposition was calculated by dividing the stained area by the total surface and quantified by 
computerized image analysis (Diskus software, Hilgers, Königswinter) and Leica Qwin 
Imaging software (Leica Ltd, Cambridge, UK). 
______________________ 
4% PFA: 
1 liter: 40g PFA, 50g Succrose, 40ml of 500mM EDTA, 100ml 10x PBS 
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2.7.6 IMMUNOFLUORESCENCE 
The relative content of macrophages, T cells, SMCs, and neutrophils was determined by 
monoclonal Ab (mAb) staining of 5 μm transversal tissue sections of aortic roots for MOMA-2, 
CD3, smoothelin and Ly6G (2.4.1), respectively. In addition, staining for Myeloperoxidase and 
MMP-9 (2.4.1) were performed using the specific mAbs as indicated. Stainings were 
visualized by fluoresceinisothiocyanate- or cyanine-3-conjugated secondary Abs (2.4.3). 
Appropriate IgG antibodies served as isotype controls. Apoptotic nuclei were detected by 
terminal deoxynucleotidyl nick-end labeling (TUNEL-kit, Roche). PDCs were detected by 
staining for Siglec-H (440c, HyCult Biotech). A rabbit anti-Cramp Ab (Innovagen) was used to 
detect Cramp on acetone fixed fresh frozen sections. Plaque IgG was detected using a 
biotinylated rabbit anti-mouse IgG (Vector Laboratories) followed by a streptavidin-conjugated 
Alexafluor-555 (Molecular Probes) on 4% paraformaldehyde-fixed frozen sections. Nuclei 
were counter- stained by 4',6-Diamidino-2-phenylindol (DAPI). Collagen was stained using 
Sirius red (Polysciences, Inc., Warrinton, PA, USA). Images were recorded with a Leica DMLB 
fluorescence microscope and CCD camera. 
 
2.8 FUNCTIONAL ASSAYS 
2.8.1 APOPTOSIS AND CELL CYCLE ASSAYS 
Peritoneal macrophages or neutrophils sorted from the air pouch lavage, blood and bone 
marrow were cultured in cell culture medium (2.5). Cells were seeded at 1 x 106 cells/ml and 
analyzed at 0, 12, 36, 60 and 84 hours of culture by staining with Annexin V (BD Bioscience) 
in the appropriate staining buffer (BD Bioscience) or propidium iodide (10 µg/ml) in PBS buffer 
containing 0.25 % TritonX-100 and RNase A (4 µg/ml; GenScript, Piscataway,NJ, USA) 
following fixation with 70 % ethanol. Apoptosis and cell cycle were assessed by FACS 
analysis using a FACS Calibur (BD Biosciences).  
 
2.8.2 PHAGOCYTOSIS ASSAYS 
Peritoneal macrophages harvested after peritonitis (2.9.3) were seeded at 1 x 106 cells/ml into 
96-well plates and incubated with di-labeled oxLDL (10µg/ml) (Intracel) or calcein- (Invitrogen) 
labeled apoptotic neutrophils (sorted from bone marrow 2.5.5) (1:1 ratio) for 1 h. Neutrophils 
were rendered apoptotic by serum deprivation over night and apoptosis was confirmed by 
Annexin V binding (>95%). Phagocytosis of apoptotic neutrophils and di-oxLDL was analyzed 
by FACS. 
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Isolated pDCs (2.5.3) seeded at 1 x 105 cells/200μl in flat bottom 96-well plates and incubated 
with di-labeled oxLDL (10µg/ml) for 12 h and analyzed by FACS. 
 
2.8.3 IN VITRO STIMULATION OF PDCS 
Isolated pDCs were seeded at 1 x 105 cells/200μl into flat bottom 96-well plates in cell culture 
medium (2.5) supplemented with 25 ng/ml FLT3-L (Peprotech) and were stimulated with 10μg 
Cramp (1ug/μl, Innovagen), 2 μg DNA (1 ug/μl, Zyagen), 1μg ODN 1585 (1μg/μl, Invivogen), 
10μg oxLDL or di-oxLDL (1ug/μl), and 4ul of mouse serum containing high (36 Units/μl) or low 
(1 Unit/μl) titers of anti-dsDNA antibodies per well for 12 h. For the generation of complexes, 
10μg of Cramp was mixed with 2 μg self-DNA in 20 μl of PBS and incubated for 15 min at 
room temperature asdescribed by Ganguly et al.171. Apoptotic (dead) PMN used for 
stimulation purposes were rendered apoptotic by UV-light treatment for 6 min at a 
concentration of 1 x 106 cells/ml in cell culture medium. PMN and pDCs were cocultured at 
ration of 5:1. 
 
2.9 ANIMAL MODELS 
All animal experiments were approved by the local ethical committee and carried out in 
accordance with the guidelines of the “Landesamt für Natur, Umwelt und Verbraucherschutz” 
North Rhine-Westphalia. 
2.9.1 MOUSE MODELS OF ATHEROSCLEROTIC DISEASE 
Female Apoe-/- or Ldlr-/-mice were fed a normal chow or, at 8 weeks of age, an atherogenic 
diet containing 21% fat and 0.15% cholesterol (Atromin) for 4 to 12 weeks depending on the 
experimental setup. After sacrificing the mice hearts were harvested by in situ perfusion 
fixation with 4% PFA. The extent of atherosclerosis was assessed in aortic roots and 
thoracoabdominal aortas by staining for lipid deposition with Oil-red-O (2.7.5). The relative 
content of macrophages, neutrophils, CD3+T cells and SMCs was determined by 
immunofluorescence (2.7.6). 
 
2.9.1.1 CELL DEPLETION ASSAYS  
PMN depletion in Ldlr-/- mice was performed by intaperitoneal injections of mAb RB6-8C5 (100 
μg/mouse, BioXCell) over 5 weeks every second day accompanied by atherogenic diet 
feeding of the mice for 5 weeks. Efficiency and specificity of PMN depletion was confirmed by 
flow cytometry analysis of blood samples. PDC depletion in Apoe-/- mice was performed by i.v. 
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injection of mAB PDCA-1 (500ug/mouse, Miltenyi) at day 1 and day 7 or day 30 and 37 
depending on the experimental setup. Mice were put on an atherogenic for 4 or 8 weeks. 
Efficiency and specificity of pDC depletion was confirmed by flow cytometry analysis of 
representative lymph nodes. 
 
2.9.1.2 CELL STIMULATION ASSAYS 
PDC stimulation in Apoe-/- mice was carried out with the i.v. injection of the oligodinucleotide 
CpG1585 (ref. to 2.5) (25ug/mouse, Inovagen) complexed to DOTAP (15ug/mouse, Roche) 3 
times a week for 4 or 8 weeks. During injections Apoe-/- mice were fed a high fat diet. Efficient 
pDC stimulation was confirmed by determining the IFNα concentration in serum. Alternatively 
Apoe+/+ mice were injected with the same dose, but sacrificed 4, 12 or 24 after injection of 
CpG complexed to DOTAP. Another set of Apoe-/- was injected with murine IFNα (100 000 
Units/mouse, HyCult Biotec) twice a week i.p. for 4 weeks together with high fat diet feeding. 
 
2.9.2 BONE MARROW TRANSPLANTATION 
To assess the contribution of IRF8 and CRAMP to lesion progression, Apoe-/- or Ldlr-/- mice 
were lethally irradiated and reconstituted with bone marrow of Irf8-/- and Cramp-/- mice. For 
bone marrow transplantations femurs and tibias were aseptically removed from donor Irf8-/-, 
and Cramp-/-or Apoe-/- and Ldlr-/- control mice. Bone marrow cavities were flushed and single 
cell suspensions prepared. Donor cells (5 × 106) were administered by tail vein injection into 
the recipient mice 24 h after an ablative dose of whole-body irradiation (2x6 Grays(Gy)). After 
recovery for 4 weeks the transplanted mice were fed a HFD over 4-12 weeks depending on 
the experimental setup. After sacrificing the mice, hearts and thoracoabdominal aortas were 
harvested and stained for lipid deposition (2.7.5). Additionally blood, lymph nodes, spleen and 
femur were removed for further analysis of different cell populations in flow cytometry assays 
(2.7.1).  
 
2.9.3 PERITONITIS 
Irf8-/- and irf8+/+ mice were injected with thioglycollate broth intraperitonealy and peritoneal 
macrophages were harvested and isolated after 4 days as described.172 Sterile 3% 
thioglycollate was prepared by autoclaving and was stored at room temperature in the dark for 
at least 6 month before use. Mice received i.p. injections of 1 ml of thioglycollate broth or PBS 
as control. 
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2.9.4 SUBCUTANEOUS AIR POUCH 
For recruitment of pDCs and neutrophils to a subcutaneous air pouch39 mice were injected at 
day 0 and 4 with 5 ml sterile air subcutaneously in the back. At day 7, 1 ml sterile PBS 
containing PAF (1µM, Biomol), TNFα (50ng/ml, Peprotech), IFNα (100ng/ml, PBL 
Laboratories) or PBS alone were injected into the pouch. 4 h or 18 h later the pouch was 
lavaged with 5 ml of ice-cold HBSS containing 0.3 mM EDTA and 0.1 % BSA. Thereafter, 
cells in the lavage fluid were counted manually using a Neubauer chamber and processed for 
FACS analysis as described before (2.7.1). 
 
2.9.5 T CELL PROLIFERATION IN VIVO 
CD4+ T cells were isolated from spleen and LNs of OT-II mice using the CD4+ T cell isolation 
kit (Miltenyi Biotec) (2.5.4). CD4+ OT-II cells were labeled with CFSE (Fluka) by incubation 
with 5 μM CFSE in labeling medium for 10 min. Labeling was stopped by adding one volume 
of labeling medium, and cells were washed an additional two times. Subsequently, 5 x 106 
CD4+ CFSE+ OT-II cells were injected into the tail vein of each wt recipient mouse. One day 
after T cell injection, ex vivo isolated pDCs (2.5.3) were pulsed with 6μg/ml OVA2 peptide for 
45 minutes for MHC class II-restricted T cell stimulation. Untreated pDCs were used as 
control. 1 x 105 pDCs were applied to recipient mice by footpad injection. Three days later, 
single-cell suspensions of popliteal LNs were prepared and the T cell proliferation was 
monitored by CFSE dye dilution using flow cytometry. 
___________________ 
Labeling medium: 
RPMI 1640, 10% FCS 
2.10 DATA ILLUSTRATION AND STATISTICAL ANALYSIS 
Data are expressed as mean ± SD and analyzed by Student‟s t-test, ANOVA with Newman-
Keuls or Dunnett‟s multiple comparison test, non-parametric Mann-Whitney test or Kruksal-
Wallis test with Dunn‟s post-hoc test, as appropriate. Data for ROS measurement were 
analyzed with two-way repeated measures analysis of variance (ANOVA; treatment  time) 
followed by planned comparisons. Differences of ρ<0.05 were considered to be statistically 
significant. All data was processed and displayed with GraphPad Prism 5 software. 
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3. RESULTS 
3.1 RESULT OUTLINE 
The following section will explain and display the experimental results, which were obtained 
throughout this thesis. 
 
The first part will describe experiments and subsequent conclusions carried out to unveil the 
participation of PMN in atherosclerosis. Neutrophils were detected and characterized with the 
help of different antibodies, which not only enable their discrimination by flow cytometry, but 
also allow visualization of PMN in tissue sections. Furthermore, in depth analysis of PMN 
activation and the subsequent examination of their granule proteins in the context of 
atherosclerosis will reveal a broader view of their contribution to plaque formation. In addition, 
analysis of apoptosis and proliferation rates as well as systemic PMN depletion will deepen 
our understanding of their role in atherosclerosis. 
 
The second part illustrates the experimental setup chosen to gain insight in the role of pDCs in 
lesion development. Specific antibodies allow the identification of pDCs in various organs and 
their detection in atherosclerotic lesions. Moreover, oligonucleotides facilitate pDC stimulation 
in vivo and thus enable us to analyse the consequences of pDC activation in atherosclerosis. 
To complement these findings, the effect of pDC depletion on atherosclerotic lesion formation 
was studied. In this context the potency of pro-atherogenic stimuli such as oxLDL to promote 
pDCs activation was examined. Ultimately, the mechanisms known to drive pDC activation in 
autoimmune diseases will be explored in the context of atherosclerosis. 
 
For a better overview of the result section the following flow chart outlines the experimental 
setup for each of the two projects. 
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Chronic myelogenous leukemia-like 
disease due to hematopoietic IRF8-
deficiency fuels atherosclerosis in mice
Activated plasmacytoid dendritic cells 
accelerate early atherosclerotic
lesion formation
Phenotypical analysis of Apoe-/- mice
transplanted with Irf8-/- bone marrow
Evaluation of lesion development
and composition in Irf8-/-►Apoe-/- mice
Characterization of Irf8-/- monocytes and
macrophages in an acute (air pouch) and 
prolonged (peritonitis) inflammation model
Examinaton of neutrophil recruitment to
an acute inflammation (air pouch) and 
determination of apoptosis, proliferation and 
activation of neutrophils in Irf8-/- mice
Determination of apoptosis and proliferation 
in peritoneal macrophages of Irf8-/- mice
Evaluation of lesion development and 
composition in Irf8-/- ►Ldlr-/- mice in 
comparison to Irf8-/- ►Ldlr-/- mice with 
neutrophil depletion
Does IRF8 influence plaque 
development?
Are monocyte and macrophage 
functions impaired?
Do neutrophils function normally?
Does neutrophil depletion revert the 
atherosclerotic phenotype?
Immunhistochemistry of aortic roots and 
FACS analysis of Apoe-/- aortas
Phagocytosis and stimulation assays with 
oxLDL treated pDCs
Antigen specific T cell proliferation assay in 
vivo
in vitro stimulation of ex vivo isolated pDCs 
with the antimicrobial peptide Cramp in 
combination with or without DNA
Evaluation of lesion development  in Ldlr-/-
mice transplanted with Cramp-/- bone 
marrow or in Apoe-/- stimulated with 
Cramp+DNA complexes
Are pDCs present in atherosclerotic 
lesions?
Does oxLDL treatment alter the function 
of pDCs in vitro and in vivo?
Are autoimmune mechanisms involved 
in pDC stimulation?
-Cramp-
-anti-dsDNA-antibodies-
Measurement of serum anti-dsDNA titer in 
all treated animals 
In vitro stimulation of pDCs with sera high or 
low in anti-dsDNA  antibody titers 
Evaluation of lesion development  and 
composition in Apoe-/- mice with specific 
pDC depletion or stimulation
Does pDC depletion or stimulation 
change plaque development?
 
Summary of the experimental setup in order of the questions addressed. 
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3.2 ROLE OF HEMATOPOIETIC IRF8 IN ATHEROSCLEROTIC LESION FORMATION 
AND ITS EFFECTS ON MONOCYTE/MACROPHAGE AND PMN FUNCTIONS 
RELATED TO ATHEROSCLEROSIS 
IRF8 is exclusively expressed in hematopoietic cells and critical in lineage determination and 
development of myeloid cells. Furthermore, it is essential in directing monocyte and 
macrophage differentiation, but is repressing genes promoting granulocytic differentiation and 
maturation.164,173,174 In consequence Irf8-/- mice develop a chronic myeloid leukemia (CML)-like 
syndrome with a striking increase in PMN numbers, while monocytes and macrophage 
numbers are significantly reduced and functionally compromised.164,174-176 Therefore we took 
advantage of the increased number of PMN in Irf8-/- mice and reconstituted lethally irradiated 
Apoe-/- mice with bone marrow of Irf8-/- mice to study the effect of hematopoietic IRF8 
deficiency and the impact of increased PMN counts in atherosclerotic lesion formation. 
 
3.2.1 APOE-/- MICE TRANSPLANTED WITH IRF8-/- BM DISPLAY A CML-LIKE 
PHENOTYPE 
As Kallies et al. reported that Irf8-/- monocytes exhibit an only marginal expression of CD115, 
possibly related to its enhanced proteolytic degradation177, a new gating strategy had to be 
established to distinguish between PMN and monocytes in these mice. This strategy identified 
monocytes by staining for CD11b and Gr1high/low but the absence of PMN-specific Ly6G, while 
PMN expressed CD11b, Gr1, and Ly6G (Figure 3-1). 
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Figure 3-1. Gating strategy for monocytes in Irf8
-/-
 mice. 
Gating strategy for PMN (Ly6G
+ 
CD11b
+ 
Gr1
+
) and monocytes (Ly6G
-
 CD11b
+
 Gr1
high/low
); 
representative dot plots are shown. 
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Next it was investigated whether or not the phenotype of Irf8-/- mice164 is retained in Apoe-/-
mice transplanted with Irf8-/- bone marrow. For this purpose relative leukocyte distribution was 
examined by flow cytometry identifying neutrophils and monocytes as described, DCs by 
staining for MHCII and CD11c, while T cells and B cells were defined by CD3 and CD19 
expression, respectively. CD45 was used as a pan marker for all leukocytes. Absolute 
numbers of leukocytes in blood of Irf8+/+►Apoe-/- and Irf8-/-►Apoe-/-were analyzed according to 
the method section 2.5.6. Similar to the distribution of peripheral blood cells in donor Irf8-/-
mice, lethally irradiated Apoe-/- mice reconstituted with Irf8-/- BM (Irf8-/-►Apoe-/-) displayed a 
trend for expansion in the number of leukocytes and a significant increase in the frequency of 
PMN in peripheral blood, while relative numbers of circulating monocytes, DCs and T cells but 
not B cells were reduced when compared to Irf8+/+►Apoe-/- mice (Figure 3-2).  
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Figure3-2. Leukocyte distribution in blood of IRF8
-/-
 Apoe
-/-
 mice. 
(a) FACS analysis of the CD45
+
 subset distribution in blood of Irf8
-/-
►Apoe
-/-
 (n=7) and Irf8
+/+
►Apoe
-/-
 
mice (n=10) after 12 weeks of high fat diet; (b) total leukocyte counts in BM-recipients. (c) relative 
frequencies of PMN, monocytes, T cells, B cells and dendritic cells in Irf8
-/-
►Apoe
-/-
mice. Data are 
expressed as mean±SD, **p<0.005; ***p<0.001. 
 
A comparable distribution of leukocyte subsets was also observed in the BM of transplanted 
mice, with an even more pronounced expansion of PMN in Irf8-/-►Apoe-/- mice compared to 
Irf8+/+►Apoe-/- mice, as shown by flow cytometry analysis and HE-stained bone marrow 
sections (Figure 3-3). 
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These data indicate that the CML-like phenotype observed in Irf8-/- mice is sustained in 
transplanted Irf8-/-►Apoe-/- mice, allowing the investigation of its consequences in 
atherosclerosis. Of note, no changes in the nuclear morphology of PMN were observed in 
blood smears of Irf8-/-►Apoe-/-and Irf8+/+►Apoe-/- mice (Figure 3-4). This is in line with a 
chronic disease course with no signs of an accumulation of progenitor or immature myeloid 
cells in blood, which would be a characteristic of the late progressive blast phase.164,178 
granulocytes
lymphocytes
Irf8+/+ Apoe-/- Irf8-/- Apoe-/-
100x 100x20x 20x
 
Figure 3-4. Representative Blood Smears. 
Representative blood smears of Irf8
+/+
►Apoe
-/-
 and Irf8
-/-
►Apoe
-/-
 mice. PMN and lymphocytes are 
indicated by black or red arrow heads, respectively.  
 
3.2.2 INCREASED ATHEROSCLEROTIC LESION FORMATION IN IRF8-/- APOE-/-MICE 
Following the confirmation of a neutrophilic phenotype in Irf8-/-►Apoe-/-mice, serum lipid levels 
and the degree of atherosclerotic lesion formation in Irf8-/-►Apoe-/-mice and controls were 
analyzed after 12 weeks of HFD. Total serum cholesterol and low density lipoprotein (LDL) 
levels were increased in Irf8-/-►Apoe-/- in comparison to Irf8+/+►Apoe-/- mice (Table 1). 
Furthermore the quantification of lipid depositions in en face preparations of aortas and aortic 
roots with oil-red-O revealed a significant exacerbation in lesion formation in Irf8-/-►Apoe-/- 
compared to Irf8+/+►Apoe-/- mice (Figure 3-5). 
 
 
Figure 3-3. Leukocyte 
distribution in bone 
marrow of Irf8
-/-
 Apoe
-/-
 
mice. 
Representative HE-stained 
sections of Irf8
+/+
and Irf8
-/- 
bone marrow recipients and 
FACS analysis of the CD45
+
 
subset distribution in bone 
marrow of Irf8
+/+
►Apoe
-/-
 
(n=10) and Irf8
-/-
►Apoe
-/-
 
mice (n=7) after 12 weeks of 
high fat diet.  
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Table 3-1. Serum lipid levels 
 total cholesterol 
[mg/dL] 
LDL 
[mg/dL] 
HDL 
[mg/dL] 
triglycerides 
[mg/dL] 
Irf8+/+ ►Apoe-/- 196.3 ± 84.5 123.5 ± 57.6 104.2 ± 45.0 84.5 ± 32.3 
Irf8-/-►Apoe-/- 298.2 ± 80.8* 198.5 ± 53.7* 111.2 ± 43.2 73.5 ± 12.6 
     
Irf8+/+►Ldlr-/- 250.8 ± 44.1 121.9 ± 19.2 91.3 ± 6.8 138.7 ± 62.9 
Irf8-/-►Ldlr-/- 249.2 ± 25.9 121.8 ± 12.3 82.4 ± 33.5 107.3 ± 26.0 
Irf8-/-►Ldlr-/-anti-PMN 324.6 ± 34.3 127.2 ± 102.5 100.5 ± 9.0 95.0 ± 28.9 
 
LDL, low-densitiy lipoprotein 
HDL, high-density lipoprotein       * p<0.05 
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Figure 3-5. Increased atherosclerotic lesion formation in Irf8
-/-
►Apoe
-/- 
mice. (a, b) Quantification 
of oil-red-O
+
 lipid depositions in the thoracoabdominal aorta (a) and aortic root (b) of Irf8
+/+
►Apoe
-/-
(n= 
10) and Irf8
-/-
►Apoe
-/-
(n=7) mice; representative images are displayed. Data is expressed as mean±SD, 
**p<0.01, ***p<0.001. 
 
To clearly attribute the changes in lesion size to the lack of IRF8 in our transplantation model 
we also investigated the effect of 12 weeks HFD in Irf8+/+ and Irf8-/- control mice without an 
Apoe-/- background. These mice showed a similar tendency in plaque development after 12 
weeks, even though they had very small lesions only detectable in aortic roots (Figure 3-6). In 
conclusion, IRF8-deficiency increases plaque formation. 
 
Figure 3-6. Increased plaque formation in Irf8
-/-
 control 
mice.Quantification of oil-red-O
+
 lipid depositions in aortic roots of 
Irf8
+/+-
 (n= 4) and Irf8
-/-
 (n=4) mice. Data is expressed as mean±SD, 
*p<0.05. 
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Augmented plaque formation may also be accompanied by changes of plaque composition, 
plaque stability (SMC content), foam cell formation (macrophage content), and leukocyte 
accumulation. Further analysis of the cellular plaque composition by quantitative 
immunofluorescence showed that the number of macrophages (MOMA+), SMC (smoothelin+), 
and T cells (CD3+) was not altered in aortic root plaques, whereas a significant increase in the 
relative number of PMN (Ly6G+) was observed in lesions of Irf8-/-►Apoe-/- (Figure 3-7). 
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Figure 3-7. Quantitative analysis of plaque composition in Irf8
+/+
 Apoe
-/-
 and Irf8
-/-
 Apoe
-/-
 . 
Quantification of macrophages, SMC-content, T cells and PMN in aortic root plaques. Data is 
expressed as mean±SD, *p<0.05. 
 
Increased neutrophil numbers may also be accompanied by enhanced granule protein 
formation and deposition. Hence, it was investigated if PMN-granule proteins were detectable. 
Both, the expression of MPO, known to be involved inROS formation (1.2.1.1), and the 
number of MMP-9+ cells (MMP-9 facilitates PMN transmigration, 1.2.1.1) were found to be 
increased (Figure 3-8). Instead, the content of collagen-rich, extracellular matrix, evidenced by 
Sirius-red staining, was reduced in lesions of Irf8-/-►Apoe-/- mice, implying a more 
inflammatory and unstable plaque phenotype (Figure 3-9). These results indicate that 
increased PMN accumulation accompanied by augmented levels of PMN-derived granule 
proteins drive plaque growth and weaken the fibrous cap. 
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Figure 3-8. MMP-9 and MPO-expressing cells and collagen content in atherosclerotic lesions. 
(a, b) Aortic root plaques of Irf8
-/-
►Apoe
-/-
 and Irf8
+/+
►Apoe
-/-
 mice were analyzed after 12 weeks of 
high fat diet. Representative images of staining for MMP-9
+ 
(a) and MPO
+
 cells (b); cell nuclei are 
stained by DAPI. (c) Representative images of collagen content Sirius red staining. 
 
In addition, ongoing inflammation in atherosclerotic plaques is accompanied by the 
accumulation of dead cell debris, referred to as the necrotic core. Growing necrotic cores are 
one major reason for increased lesion sizes. Therefore we measured the necrotic core area 
and the amount of DNA fragmentation within the plaque by TUNEL staining. Notably, the size 
of necrotic cores in lesions of Irf8-/-►Apoe-/- mice as well as their number of lesional TUNEL+ 
apoptotic cells was markedly increased in comparison to Irf8+/+►Apoe-/- mice (Figure 3-9; a). 
To further unravel the cell type undergoing apoptosis or necrosis, double-immunofluorescence 
staining was performed. While the macrophage fraction within TUNEL+ cells did not differ, a 
clear increase in relative numbers of TUNEL+ Ly6G+ PMN could be detected in Irf8-/-►Apoe-/- 
compared to Irf8+/+►Apoe-/- lesions (Figure 3-9; b,c). These results demonstrate that 
exacerbated atherosclerotic lesion formation in Irf8-/-►Apoe-/- mice is associated with an 
enhanced accumulation and subsequent apoptosis of PMN within growing plaques. 
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Figure 3-9. Necrotic cores and TUNEL
+
 cell numbers are increased in Irf8
-/-
 Apoe
-/-
 lesions. (a) 
Quantification of acellular necrotic cores and TUNEL
+
 apoptotic cells within aortic root lesion of 
Irf8
+/+
►Apoe
-/-
 and Irf8
-/-
►Apoe
-/-
 mice, and (b) quantification of double-positive TUNEL
+
 macrophages 
and TUNEL
+ 
PMN relative to total TUNEL
+
 cells (n=7-10).(c) Representative images of Ly6Gand 
TUNEL double-immunofluorescence staining. Cell nuclei were stained by DAPI. Data is expressed as 
mean±SD, *p<0.05. 
 
3.2.3 MACROPHAGE FUNCTIONS BUT NOT ACCUMULATION OR APOPTOSIS ARE 
IMPAIRED IN IRF8-/-MICE 
Macrophage phenotype and functions were shown to be regulated by IRF8.173 Thus, the 
question arose whether macrophage functions and/or their accumulation under acute and 
prolonged inflammatory conditions, reflecting inflammation in atherosclerosis, would be 
altered. To address this question, we first investigated acute inflammatory recruitment into a 
subcutaneous air pouch. Results therefrom revealed an increase in the total number of 
leukocytes accumulating in air pouches of Irf8-/- mice in response to PAF after 4 hours and a 
significant decrease in relative frequencies of monocytes compared to Irf8+/+ mice (Figure 3-
10; a,b). Instead, the absolute number of monocytes extravasated into the air pouch did not 
differ in Irf8+/+ or Irf8-/- mice contrasting decreased absolute and relative monocyte counts in 
peripheral blood (Figure 3-10; b). 
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Figure 3-10. Macrophage recruitment in acute inflammation is not affected in Irf8
-/- 
mice. (a) Total 
count of cells retrieved from air pouches after stimulation with PAF for 4 h. (b) Representative FACS dot 
plots of monocytes (gated events, inserted numbers indicate percentages relative to CD45
+
 cells) in 
blood and air pouch lavages of Irf8
+/+
 and Irf8
-/-
 mice (n=5 each) 4 h after stimulation with PAF. Absolute 
monocyte counts in blood and air pouch lavages are depicted in bar graphs. Data is expressed as 
mean±SD, *p<0.05. 
 
Prolonged inflammation was studied in the peritonitis model by flow cytometry analysis of 
peritoneal macrophage numbers before thioglycollate injection (untreated) and 4 days after 
thioglycollate injection. These data did not reveal any difference between Irf8-/- peritoneal 
macrophages and the control group (Figure 3-11).  
 
Figure 3-11. Recruitment 
of Irf8
-/-
 macrophages is 
not altered under 
prolonged inflammatory 
conditions. Representa-
tive FACS dot plots of 
monocytes (gated events, 
inserted numbers repre-
sent percentages relative 
to CD45
+
 cells) in 
unstimulated and thio-
glycollate-injected Irf8
+/+
 
and Irf8
-/-
 mice (n=5 each). 
Absolute macrophage 
counts are depicted in bar 
graphs. Data is expressed 
as mean±SD, *p<0.05. 
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Moreover no differences were detectable for the apoptosis rate of Irf8-/- peritoneal 
macrophages compared to Irf8+/+ macrophages (Data not shown). In summary, these results 
suggest that inflammatory monocyte recruitment under acute or chronic conditions is not 
impaired and apoptosis and proliferation rates are not altered in IRF8-deficient mice. 
 
Further, we examined an IRF8-related impact on macrophage phenotype analyzing the 
surface expression of major histocompatibility complex class II (MHCII), co-stimulatory 
molecule CD40 and scavenger receptors in peritoneal macrophages from Irf8+/+ or Irf8-/- mice 
by FACS analysis. The expression of MHCII and CD40 (Figure 3-12) but also surface class B 
scavenger receptor CD36 were significantly decreased in peritoneal macrophages of Irf8-/-
macrophages compared to Irf8+/+ controls, while the expression of class A scavenger 
receptors CD68 and CD204 were not affected (Figure 3-13).  
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Figure 3-12. Decreased expression of MHCII and CD40 on Irf8
-/-
 macrophages. FACS analysis and 
representative histograms of MHCII and co-stimulatory CD40 expression by peritoneal macrophages 
isolated from Irf8
+/+
 (black line) or Irf8
-/-
 mice (red line) (n=5 each). Filled histograms (grey) represent 
FMO controls. Quantification of staining is shown as MFI relative to expression by Irf8
+/+
 macrophages. 
Data are expressed as mean±SD, ***p<0.001. 
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Figure 3-13. Decreased expression of CD36, but not CD68 and CD204 in Irf8
-/-
 macrophages. 
FACS analysis and representative histograms of CD36, CD68 and CD204 expression by peritoneal 
macrophages isolated from Irf8
+/+
 (black line) or Irf8
-/-
 mice (red line) (n=5 each). Filled histograms 
(grey) represent FMO controls. Quantification of staining is given as MFI relative to expression by Irf8
+/+
 
macrophages. Data are expressed as mean±SD,  ***p<0.001. 
 
 
 
3 RESULTS 
 
 48 
CD36 is one the most important receptors for the uptake of oxLDL and the clearance of 
apoptotic cells.179,180 Therefore one may ask whether phagocytosis of oxLDL or apoptotic 
debris by Irf8-/- macrophages would be affected by a reduced expression of CD36. To address 
this question labeled oxLDL or apoptotic PMN were incubated with peritoneal macrophages 
isolated from Irf8+/+ or Irf8-/- mice for 1 h. Flow cytometry analysis of these cells revealed a 
significantly decreased phagocytosis of both - oxLDL and apoptotic neutrophils when 
comparing Irf8-/-to Irf8+/+macrophages (Figure 3-14). 
 
Figure 3-14. Decreased phago-
cytic capacity of Irf8
-/-
 
macrophages. FACS analysis and 
representative historgrams of 
peritoneal macrophages isolated 
from Irf8
+/+
 (black line) or Irf8
-/-
 mice 
(red line) incubated with di-oxLDL 
and calcein-labelled apoptotic PMN 
for 1 h in comparison to untreated 
control macrophages (grey, filled 
histogram). Uptake efficiency is quantified by analyzing mean fluorescence intensity (MFI) and 
expressed relative to Irf8
+/+
 mice (n=5 each). Data are expressed as mean±SD,*p<0.05; ***p<0.001. 
 
In addition, phagocytosis of apoptotic cells is known to exert immunosuppressive effects by 
inducing the production of anti-inflammatory cytokines including IL-10 in phagocytes.181 Thus, 
Irf8-/- and Irf8+/+ peritoneal macrophages were incubated in the presence of apoptotic PMN for 
12 h. Subsequent analysis of the cell culture supernatant by ELISA showed a strong secretion 
of IL-10 by Irf8+/+ macrophages in response to the uptake of apoptotic PMN, but IL-10 release 
was substantially impaired in Irf8-/- macrophages (Figure 3-15). 
 
 
 
Figure 3-15. Impaired IL-10 secretion byIrf8
-/-
macrophages. Peritoneal macrophages from Irf8
+/+
 
or Irf8
-/-
 mice were incubated with apoptotic PMN for 
12 h and IL-10 concentrations assessed in the cell-
free supernatant by ELISA (n=5 each); n.d., non 
detectable. Data are expressed as 
mean±SD,*p<0.05. 
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These differences may also relate to reduced IL-10 serum levelsin Irf8-/-►Apoe-/- compared to 
Irf8+/+►Apoe-/- mice (Figure 3-16; a). Moreover, lower concentrations of IFN and IL-6 were 
observed in air pouches of Irf8-/- in comparison to Irf8+/+mice (Figure 3-16; b), suggesting a 
global insufficiency in cytokine production in Irf8-/- macrophages.  
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Figure 3-16. Cytokine production is impaired in Irf8
-/-
 mice. (a) Serum IL-10 concentrations in Irf8
-/-
►Apoe
-/-
 and Irf8
+/+
►Apoe
-/-
 mice (n=7-10) after 12 weeks of HFD determined by ELISA. (b) IFN and 
IL-6 concentration in air pouch lavages of Irf8
+/+
 or Irf8
-/- 
mice 4 h after the injection of PAF (n=5 each). 
Data are expressed as mean±SD, *p<0.05, **p<0.01. ***p<0.001. 
 
In summary, although apoptosis and proliferation rates are not altered in Irf8-/- macrophages, 
their functionality is impaired, as demonstrated by decreased expression of CD36 in line with 
reduced uptake of oxLDL and apoptotic PMN accompanied withlimited production of IL-10, 
IFN and IL-6. 
 
3.2.4 THE INFLAMMATORY ACCUMULATION OF IRF8-/- PMN IS DUE TO ENHANCED 
EXTRAVASATION 
 
Taking into account, that macrophages are functionally impaired in Irf8-/- mice, but lesion size 
is increased in Irf8-/-►Apoe-/- transplanted animals, a more detailed analysis of how PMN may 
drive plaque progression is necessary. 
The enhanced frequency of PMN in Irf8-/-►Apoe-/- aortic root plaques led us to further address 
the recruitment of PMN. Similarly, the number of emigrated PMN in the air pouch lavage in 
response to PAF was significantly increased in Irf8-/- mice after 4 h (Figure 3-17). However, the 
ratio of PMN numbers in blood relative to air pouches was identical in either strain 
(0.37±0.04in Irf8+/+vs. 0.40±0.09 in Irf8-/- mice), suggesting that PMN are recruited with similar 
efficiencies and that their enhanced accumulation at sites of inflammation in mice with Irf8-/- 
BM reflects an influx proportional to their numbers in blood.  
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Figure 3-17. Accumulation of 
PMN in Irf8
-/-
 mice is due to their 
enhanced extravasation. 
Representative FACS dot plots of 
PMN (gates events, inserted 
numbers indicate percentages 
relative to CD45
+
 cells) in blood and 
air pouch lavages 4 h after PAF 
stimulation in Irf8
+/+
 and Irf8
-/-
 mice 
(n= 5 each). Absolute PMN counts 
in blood and air pouch lavages are 
depicted in bar graphs representing 
mean±SD, **p<0.01, *** p<0.001. 
 
 
 
 
An increased frequency of apoptotic PMN in Irf8-/-►Apoe-/- lesions (Figure 3-9) may indicate 
an enhanced susceptibility of Irf8-/-PMN to undergo cell death. While fewer apoptotic blood 
and air pouch-derived Irf8-/- PMN could be detected early after the induction of serum 
starvation, no differences were detectable after 36 h with about 50% Annexin V+ PMN, and at 
later time points, as revealed by FACS analysis and when compared to Irf8+/+ PMN (Figure 3-
18; a). Of note, bone marrow-derived Irf8-/- PMN were less susceptible to apoptosis compared 
to Irf8+/+controls (not shown), confirming previous findings.175 Enhanced proliferation of 
extravasated cells may yet be another mechanism contributing to PMN accumulation. Cell 
cycle analysis of PMN from blood and air pouches of Irf8+/+ and Irf8-/- mice, however, could not 
reveal any differences in the number of proliferating cells in the S and M phase, excluding this 
possibility (Figure 3-18; b). This indicates that apoptosis and proliferation of PMN in blood and 
at sites of inflammation are not substantially affected by the lack of IRF8. Thus, increased 
numbers of PMN and TUNEL+ PMN in atherosclerotic lesions are likely due to an overflow 
with extravasated PMN.  
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Figure 3-18. Apoptosis and 
proliferation rates do not differ 
between Irf8
-/- 
and Irf8
+/+ 
neutrophils. 
FACS analysis of the frequencies 
of Annexin V
+
 apoptotic (a) and 
propidium iodide (PI)
+ 
(b) 
proliferation cells in the S and M 
phase as determined by cell cycle 
analysis after intracellular staining 
in PMN sorted from blood and air 
pouch lavages of Irf8
+/+
 and Irf8
-/-
 
mice (n=5 each) and after serum-
starvation for indicated time 
periods. Data are expressed as 
mean±SD, *p<0.05. 
 
 
 
 
 
 
 
 
In conclusion, increased numbers of PMN within lesions are likely due to enhanced 
extravasation, but neutrophil numbers are not influenced by their apoptosis or proliferation 
rate.  
 
3.2.5 ROS FORMATION AND GRANULE DISCHARGE ARE NOT IMPAIRED IN IRF8-/- PMN 
ROS play a central role in the development of atherosclerosis and initiate and sustain key 
mechanisms of atheroprogression.182 As PMN are a major source of ROS, we assessed the 
ROS-forming aptitude of peripheral PMN FACS-sorted from blood and BM. Both the treatment 
with TNF or PMA triggered an equal release of ROS over baseline in Irf8+/+ compared to Irf8-/- 
PMN (Figure 3-19).  
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Figure 3-19. ROS formation is not impaired in Irf8
-/-
 mice. ROS release from PMN sorted from 
peripheral blood of Irf8
+/+
 and Irf8
-/-
 mice (n=5 each) in response to TNF or PMA in comparison to 
untreated cells. Lines represent ROS formation over time (measured by MFI), *p<0.05. 
 
 
PMN contain preformed granules, which are rapidly released upon extravasation. This 
process can be assessed by the upregulation of membrane-bound receptors translocated 
from the granule membrane or by measurement of granule proteins in the cell-free 
supernatant.29,146 Compared to circulating blood PMN, the surface expression of CD11b and 
CD14 derived from secretory vesicles and tertiary granules29 were markedly upregulated on 
both Irf8+/+ and Irf8-/- PMN after extravasation to the air pouch (Figure 3-20; a). 
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Figure 3-20. Granule protein discharge is not affected by lack of IRF8. (a) FACS analysis of the 
surface expression of CD11b and CD14 in PMN in blood (red line) and air pouches (black line) of Irf8
+/+
 
and Irf8
-/-
 mice. Filled histograms (grey) represent FMO controls. One representative histogram of five 
independent experiments is shown. (b) Activity of MPO and MMP-9 in air pouch lavages collected from 
Irf8
+/+
 and Irf8
-/-
 mice (n=5 for each group) after 4 hours of PAF stimulation and PMN extravasation. 
Data are expressed as mean±SD, ***p<0.001.  
 
  3 RESULTS 
 
 53 
Concentrations of MMP-9 and MPO, which are stored in primary and secondary PMN 
granules183, were found to be significantly increased in the air pouch lavage from Irf8-/- 
compared to Irf8+/+ mice (Figure 3-20, b). However, a correlation of enzyme activity with PMN 
numbers in the air pouch revealed no significant differences in the amount of enzyme released 
per cell when comparing both strains (not shown). This indicates that Irf8-/- PMN are 
functionally intact and that enhanced numbers of extravasated PMN likely contribute to an 
overall increased ROS- and granule-releasing capacity which may contribute to inflammation 
and enhanced atherosclerosis observed in Irf8-/-►Apoe-/-mice. 
 
3.2.6 PMN-DEPLETION IN IRF8-/- LDLR-/-MICE PREVENTS AGGRAVATED ATHEROS-
CLEROTIC LESION FORMATION 
To scrutinizethe contribution of PMN to aggravated lesion formation in mice reconstituted with 
Irf8-/- bone marrow, a PMN-depleting antibody was employed. Preliminary evaluation of the 
antibody depletion efficiency revealed an almost complete clearing of neutrophils from blood 4 
h after injection of 100 µg antibody i.p. in Irf8+/+and Irf8-/- mice (Figure 3-21). 
 
Figure 3-21. Antibody depletion efficiency. FACS analysis of 
the relative frequencies of PMN before (0h) and after (4h) 
treatment with PMN depletion antibody. Data are expressed as 
mean±SD, ***p<0.001 comparing 4h to 0h, # p<0.05 comparing 
0h to 0h.  
 
 
 
 
Recapitulating results obtained in transplanted Apoe-/- mice, Irf8-/-►LDL-receptor deficient 
(Ldlr-/-) mice displayed an expansion of leukocytes and a significant increase of neutrophils in 
blood and bone marrow (Figure 3-22). 
Furthermore early atherosclerotic lesionsin aortas and aortic rootsof Irf8-/-►Ldlr-/- mice after 5 
weeks of HFD also revealed enhanced plaque formation compared to Irf8+/+►Ldlr-/- mice 
(Figure 3-23; a,b). Importantly, depletion of PMN with 100 µg depletion antibody every other 
day over this time period prevented the exacerbation in lesion formation in Irf8-/-►Ldlr-/- mice 
(Figure 3-23; a,b). 
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Figure 3-22. Absolute leukocyte numbers and relative PMN frequencies in Ldlr
-/-
 BM recipients. 
(a) Total leukocyte counts in BM-recipients and (b) relative frequencies of PMN in blood and bone 
marrow of Irf8
-/-
►Ldlr
-/-
 and controls (n=5-7). Data are expressed as mean±SD, ***p<0.001.  
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Figure 3-23. PMN depletion in Irf8
-/-
 Ldlr
-/-
 mice prevents exacerbated atherosclerotic lesion 
formation. Quantification of oil-red-O
+
 lipid depositions in the thoracoabdominal aorta (a) and aortic 
roots (b) of Irf8
+/+
►Ldlr
-/-
 and Irf8
-/-
►Ldlr
-/-
 mice and inIrf8
-/-
►Ldlr
-/-
 mice treated with anti-PMN Ab after 
5 weeks of high fat diet (n=5-6 each). Data are expressed as mean±SD, *p<0.05 compared to 
Irf8
+/+
►Ldlr
-/-
 mice. 
 
 
Further analysis of the plaque composition in these bone marrow recipients revealed, that 
macrophage numbers in atherosclerotic lesions were not affected in either group. Instead,the 
enhanced accumulating of Ly6G+PMN and TUNEL+ cells in Irf8-/-►Ldlr-/- mice was 
preventedby the treatment with the PMN-depleting antibody (Figure 3-24). No changes in 
serum lipid levels were observed between the different treatments (Table 3-1), while IL-10 
serum levels were again significantly diminished in Irf8-/-►Ldlr-/- animals compared to 
Irf8+/+►Ldlr-/- mice. Irf8-/-►Ldlr-/- mice treated with a PMN depletion antibody showed an upward 
trend in IL-10 serum levels (Figure 3-25). 
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Figure 3-24. PMN depletion decreasesPMN and TUNEL
+
 cells inIrf8
-/-
 Ldlr
-/- 
lesions. Quantification 
of macrophages, PMN and TUNEL
+
 apoptotic cells in aortic root plaques. Data are expressed as 
mean±SD, *p<0.05 compared to Irf8
+/+
►Ldlr
-/-
 mice, and **p<0.01 compared to both Irf8
+/+
► Ldlr
-/-
 and 
Irf8
-/-
► Ldlr
-/-
 mice. 
 
Figure 3-25. Cytokine production is impaired in Irf8
-/-
Ldlr
-/-
mice. Serum IL-10 concentrations in Irf8
+/+
► Ldlr
-/-
andIrf8
-/-
► Ldlr
-/-
mice (n=5-6) after 12 weeks of HFD 
determined by ELISA. Data are expressed as mean±SD, 
*p<0.05. 
 
 
 
 
 
Taken together, these data establish that the expansion of PMN in blood and at sites of 
inflammation causally determines the enhanced development of atherosclerosis in mice with 
Irf8-/- bone marrow. 
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3.3 ROLE OF PLASMACYTOID DENDRITIC CELLS IN THE DEVELOPMENT OF 
ATHEROSCLEROSIS 
PDCs are a subtype of DCs, which are highly specialized for recognition of viral pathogens 
followed by the release of great amounts of type I interferons to eliminate the intruder and 
induce a general immune response. However, although TLR7 and TL9 are expressed 
intracellularly to prevent recognition of self antigens (nucleic acids), several autoimmune 
diseases are known in which pDCs and their release of type I interferons trigger disease 
progression (ref. 1.2.2.2).97 So far, the role of pDCs in atherosclerosis has only been 
marginally addressed. Although Niessner et al.154,155 showed that pDCs can be found in the 
shoulder region of human plaques, it is not clear if pDCs have a significant impact on the 
development and progression of atherosclerosis and how they are activated in this context. 
Therefore, a murine mouse model of atherosclerosis (Apoe-/-) was used to study the role of 
pDCs in atherosclerosis employing various complementary approaches. 
 
3.3.1 PDCS ARE PRESENT IN ATHEROSCLEROTIC LESIONS OF APOE-/- MICE 
Murine pDCs are described as B220+, CD11clow, CD11b-, PDCA1+ and SiglecH (440c+) of 
which the last two markers are supposed to be specific for this DC-subpopulation.86,87 PDCs 
are very low in numbers and discrimination of pDCs varies between published studies, in this 
thesis they are identified by PDCA1+ and SiglecH (440c+) as depicted in Figure 3-26 for blood, 
bone marrow, lymph node and spleen in flow cytometry analysis. 
 
Figure 3-26. Gating 
strategy and frequencies 
of pDCs in various organs. 
PDCs are identified by 
CD45
+
 PDCA1
+
 440c
+
; 
representative dot plots are 
shown (gated events, 
inserted numbers indicate 
percentages relative to 
CD45
+
 cells). 
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In addition, numbers indicated in the representative dot plots depict pDC frequencies in Apoe-/-
mice relative to all leukocytes in blood, bone marrow, lymph node and spleen, demonstrating 
that bone marrow cells are the richest source of pDCs (Figure 3-26). 
To address the question if pDCs are present in murine atherosclerotic lesions 
immunofluorescent stainings of aortic roots and spleen (positive control) of 12 week old Apoe-/-
mice fed a HFD over 4 weeks were performed. Representative images show pDCs identified 
by SiglecH (440c+) staining in spleen and aortic root (Figure 3-27). 
440c DAPI merge
440c DAPI mergeoverview
plaque
10x 40x 40x 40x
20x 20x 20x
 
Figure 3-27. Identification of pDCs in aortic roots of Apoe
-/- 
mice. Representative 
immunofluorescent images of 440c
+ 
pDCs in spleen (upper panel) and aortic root (lower panel) in an 
Apoe
-/-
 mouse are depicted. Cell nuclei were stained by DAPI.  
 
To confirm the identification of pDCs in atherosclerotic lesions of Apoe-/- mice on HFD and in 
Apoe-/- mice fed a normal chow, enzymatically digested aortas of Apoe+/+ and Apoe-/- mice 
were stained for 440c+ and PDCA1 and analysed by flow cytometry. As depicted in Figure 3-
28 (a) only few pDCs could be detected in the aorta of Apoe+/+ mice, but their frequencies 
markedly increased in Apoe-/- mice fed a high fat diet for 3 month. Furthermore, IFNα serum 
levels in Apoe-/- mice on high fat diet were significantly elevated, together with increased 
mRNA transcripts of SiglecH and Ifn in aortic tissue compared to Apoe-/- on normal chow 
(Figure 3-28; b,c). These data substantiate the presence of pDCs in murine atherosclerotic 
lesions. 
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Figure 3-28. Gating strategy and pDC frequencies in mouse aortas. (a) Representative Dot Plots of 
aorta lysates are shown, pDCs are identified by low SSC, CD45
+
 and PDCA1
+
. (b) Quantification of 
pDC numbers by flow cytometry analysis of aortas from Apoe
+/+
, Apoe
-/-
 6 month old and Apoe
-/-
 fed a 
HFD for 3 month (n= 5 per group). Data are expressed as mean±SD, ***p<0.001. 
 
3.3.2 MANIPULATION OF PDC COUNTS AND ACTIVITY CORRELATES WITH 
ATHEROSCLEROTIC LESION FORMATION 
3.3.2.1 ANALYSIS AFTER 4 WEEKS HIGH FAT DIET 
To investigate a general role of pDCs in atherosclerosis, Apoe-/- mice fed a HFD for 4 weeks 
received i.v. injections of a pDC depletion antibody (PDCA1, ref. to 2.9.1.1) at the beginning of 
HFD feeding and again after 7 days. Atherosclerotic lesion formation in the aortic root and 
aorta was substantially reduced in Apoe-/- mice treated with the PDCA1 antibody compared to 
IgG injected controls (Figure 3-29; a, b). Furthermore pDC depletion was associated with a 
decrease in the relative content of lesional macrophages (Figure 3-29; c).  
As pointed out before, pDCs are known to specifically secrete large amounts of type I 
interferons upon stimulation with CpG motives via binding murine TLR9.169 To monitor a CpG 
responst in vivo we injected 25 µg of CpG complexed to DOTAP i.v. in Apoe+/+ mice and 
examined the IFN and Chemerin serum levels as well as pDC numbers in blood, bone 
marrow, spleen and lymph node after 4h and 12 h. These data confirmed a significant 
secretion of IFNafter 4h, which was still detectable after 12h (Figure 3-30; a) and a 
significant increase of chemerin serum levels 12 h after CpG injections (Figure 3-30; b). PDC 
numbers in blood, bone marrow, lymph node and spleen were significantly increased after 4 h, 
but were lowered to control level again 12 h after treatment, indicating that pDCs numbers are 
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tightly regulated as soon as the pathogen level (“CpGs”) decreases again. Furthermore CpG 
stimulation eventually induces pDC maturation resulting in pDC emigration to sites of 
inflammation. Of note, IFN levels decreased again after 48 h (data not shown), an 
observation also reported by Swiecki et al.184 in murine cytomegalovirus infected mice. From 
these results we concluded that 3 doses of CpG motives per week would be sufficient to 
stimulate pDCs for longer time periods in vivo. 
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Figure 3-29. PDC depletion decreased plaque formation in Apoe
-/-
 mice. Quantification of oil-red-O
+
 
lipid depositions in (a) aortic roots and (b) thoracoabdominal aortas of Apoe
-/-
 mice treated with PDCA1 
Ab or Isotype control Ab. (c) Quantification of macrophage contents in aortic roots. Mice were fed a 
HFD over 4 weeks (Isotyp n=6; PDCA1 n=6-7).Representative images of aortic roots are displayed. 
Data are expressed as mean±SD; *p<0.05;** p<0.01. 
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Figure 3-30. Monitoring of an immune response after CpG treatment over time. (a, b) IFNα and 
chemerin concentrations (pg/ml) in sera of Apoe
+/+
control mice (untreated) or 4 h and 12 h after CpG 
treatment. (c-f) Quantification of pDC numbers by flow cytometry analysis of blood, bone marrow, 
lymph node and spleen in Apoe
+/+ 
control mice (untreated) or 4 h and 12 h after CpG treatment (n=5 per 
group). Data are expressed as mean±SD; *p<0.05;** p<0.01, ***p<0.005. 
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Given the presence of pDCs within atherosclerotic lesions, we further wanted to unravel 
whether a specific stimulation of pDCs would affect plaque formation. Quantification of lipid 
depositions in the aorta and aortic roots revealed a significant exacerbation in lesion formation 
in CpG-injected Apoe-/- mice compared to control treated mice (Figure 3-31; a,b), which was 
associated with a significant increase in the content of macrophages in the aortic root (Figure 
3-31; c). Notably, the CpG-induced increase in plaque formation together with the augmented 
numbers of macrophages were abrogated in Apoe-/- mice depleted of pDCs by PDCA1 
antibody injections (Figure 3-31; a-c). These data indicate that stimulated pDCs accounted for 
the effects of the CpG treatment exclusively. To confirm the assumption that IFNα secretion 
by activated pDCs promotes atherosclerosis, 6 week old Apoe-/-mice were fed a HFD over 4 
weeks accompanied by a repetitive i.p. injection of IFNα. Plaque analysis of these animals 
revealed an increase in lesion formation and macrophage content in Apoe-/- mice treated with 
IFN (Figure 3-31; c,d), suggesting that IFNα may be the main trigger of pDC-induced plaque 
formation. 
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Figure 3-31. Increased plaque formation in Apoe
-/-
 mice treated with CpGs or IFNα. Quantification 
of oil-red-O
+
 lipid depositions in (a) aortic roots and (b) thoracoabdominal aortas of Apoe
-/-
 mice treated 
with DOTAP (control), CpG and CpG+PDCA1. (c, e) Analysis of macrophage contents in aortic roots. 
(d) Quantification of oil-red-O
+
 lipid depositions in thoracoabdominal aortas of Apoe
-/-
 mice treated with 
PBS or IFNα. All mice were fed a HFD over 4 weeks (control n=9-11, CpG n=7-9, PDCA1+CpG n=5, 
PBS n= 6-7 and IFNα n=6-7). Representative images of aortic roots are given. Data is expressed as 
mean±SD, *p<0.05. 
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3.3.2.2 ANALYSIS AFTER 8 WEEKS HIGH FAT DIET 
To analyse the stage specific contribution of pDCs in atherosclerotic lesion formation, we 
depleted pDCs in Apoe-/- mice four weeks after initiation of HFD. In these experiments, pDC 
depletion did not affect the lesion size in aortic roots and aortas after an additional 4 weeks of 
HFD compared to control-treated mice (Figure 3-32 a, b). Further analysis of the plaque 
composition in these mice revealed, that macrophage numbers in atherosclerotic lesions did 
not differ in both groups (Figure 3-32; c). Surprisingly and in contrast to all other experiments 
relative and absolute T cell numbers in blood were significantly augmented in these mice 
(Figure 3-32; d), accompanied by a dramatic increase of IL-4 serum levels (Figure 3-32; e). 
These data may indicate that pDC depletion under inflammatory conditions causes side 
effects most likely masking results observed during early lesion development. 
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Figure 3-32. No change in plaque development in pDC-depleted mice with prolonged high fat 
diet. Quantification of oil-red-O
+
 lipid depositions in (a) aortic roots and (b) thoracoabdominal aortas of 
Apoe
-/-
 mice treated with Isotype IgG or PDCA1 antibody.(c) Analysis of macrophage contents in aortic 
roots.(d) Quantification of T cell numbers by flow cytometry analysis for relative and absolute 
frequencies. (e) IL-4 serum titers in IgG and PDCA1 treated mice. All mice were fed a high fat diet over 
8 weeks. Representative images of aortic roots are given. Data are expressed as mean±SD,*p<0.05, 
**p<0.01, **p<0.001. 
 
In contrast, prolonged injection of CpGs over 8 weeks, or treatment of mice already bearing 
early lesions (4 weeks of HFD prior to stimulation) with CpGs for another 4 weeks led to 
enhanced atherosclerotic plaque size in aortic roots and aortas of Apoe-/- mice. The content of 
lesional macrophages did not further increase (Figure 3-33; a-c). In conclusion these data 
demonstrate an important role of activated pDCs in the progression of lesion formation, while 
depletion of pDCs only affects early atherosclersosis. 
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Figure 3-33. Enhanced plaque formation in CpG treated mice with prolonged high fat diet. 
Quantification of oil-red-O
+
 lipid depositions in (a) aortic roots and (b) thoracoabdominal aortas of Apoe
-
/-
 mice treated with DOTAP (control) and CpGs for a period of 8 or 4 weeks. (c) The relative content of 
MOMA-2
+ 
macrophages per total plaque cells was analyzed by quantitative immunofluorescence. All 
mice were fed a HFD over 8 weeks. Representative images of aortic roots are given. Data are 
expressed as mean±SD, *p<0.05, **p<0.01. 
 
3.3.3ALTERATIONS OF PDC FUNCTIONS IN THE PRESENCE OF OXLDL TREATMENT 
Modified lipoproteins, e.g. oxLDL, accumulate in the arterial wall during atherosclerosis. Thus, 
following the confirmation of pDCs influencing atherosclerotic lesion development, it was 
addressed whether or not oxLDL could be taken up by ex vivo isolated pDCs and would alter 
their maturation and function. In addition pDCs were treated with GpG motives as a positive 
control (ref. to 2.5). In line with conventional DCs185, pDCs were capable of taking up Di-
labeled oxLDL (Figure 3-34; a). However, upregulation of costimulatory molecules was only 
observed in CpG treated pDCs, but not in the presence of oxLDL (Figure 3-34; b). On the 
other hand scavenger receptor CD36, implicated in the phagocytosis of oxLDL179,186, is 
constitutively expressed by pDCs and even further upregulated by stimulation with oxLDL or 
CpG motives. The protein expression of the scavenger receptors CD68 and SR-A was not 
altered in the prescence of oxLDL or CpGs (Figure 3-34; c).  
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Figure 3-34. Di-oxLDL uptake and MHCII, CD86 and scavenger receptor expression of oxLDL 
treated pDCs. (a) The uptake of Di-labeled oxLDL after exposure to oxLDL or PBS over 12 h was 
assessed in sorted pDCs by FACS analysis. (b, c) Expression of MHCII and CD86 and the scavenger 
receptors CD36, CD68 and SR-A in sorted pDCs. Cells were stimulated with/without oxLDL and CpG 
overnight and analysed by FACS. Representative histograms with FMO controls of 3 independent 
experiments are shown. 
 
Although pDCs are not as efficient in antigen presentation as cDCs (ref. to 1.2.2), they are 
fully capable of inducing an antigen specific T cell response.187 Therefore it was investigated if 
prestimulation of ex vivo isolated pDCs with oxLDL would alter their T cell proliferation 
capacity in vivo. As shown in Figure 3-35 (a,b) oxLDL pretreatment of pDCs for 12 h prior to 
OVA-2 feeding and subsequent foot pad injection of the cultured pDCs potentiated the 
antigen-specific T cell response in vivo to a similar extend as pretreatment with CpG motives 
for 12 h did. However, no additive effects were observed in co-cultures simultaneously treated 
with CpG and oxLDL (Figure 3-35; a, b). To further elucidate whether the enhanced T cell 
proliferation in the presence of oxLDL could be due to an altered cytokine profile, supernatants 
of treated pDCs were examined for various proinflammtory mediators by bead array analysis. 
IFN was measured by ELISA. While IFN was not detectable in supernatants of untreated T 
cells, and an only marginal expression was observed in unpulsed pDCs or in OVA-2 pulsed 
pDCs interacting with OT-II T cells, an increase in the secretion of IFN was detectable in 
pDC-T cell co-cultures upon stimulation with CpGs. OxLDL per se did not result in an increase 
in the secretion of IFN by pDCs (Figure 3-35; c) or induce IFNmRNA expression (data not 
shown). The concentrations of all other cytokines measured (e.g. IL-6, TNF) did not 
significantly vary among the different treatments (data not shown). Thus, oxLDL does not 
induce the release of proinflammatory cytokines; therefore engagement of antigen-specific T 
cell interactions in the prescence of oxLDL must be explained differently. 
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Figure 3-35. oxLDL can be taken up by pDCs and enhances pDC-driven T cell responses. (a) 
Sorted pDCs (unpulsed control), OVA-2-pulsed pDCs pretreated with or without oxLDL or CpG over 12 
h were transferred into wt mice transfused with CFSE
+
OT-II T cells. After 3 days, T-cell proliferation was 
quantified by CSFE dilution and FACS analysis; representative dot plots and percentage of CFSE
+
CD4
+
 
T cells (red markers) within gates are shown. (b) Quantificatin of T cell proliferation shown in a (n=4 
independent experiments). Data is expressed as mean±SD, **p<0.01, ***p<0.001. (c) IFNα secretion in 
supernatants of the T cell proliferation assay after 12 h in vitro culture (n=4 independent experiments). 
Data is expressed as mean±SD, *p<0.05. (d) The uptake of 488-labeled OVA-2 peptid pretreated with 
PBS, oxLDL (left panel) or CpG (right panel) over 12 h was assessed in sorted pDCs by FACS analysis; 
representative histograms with FMO controls of 3 independent experiments are shown. 
 
Hence, it may be possible that oxLDL promotes T cell proliferation by enhancing the 
phagocytic uptake of antigens, e.g. by inducing the expression of scavenger receptors as 
already shown for CD36 (Figure 3-34;c). Following this assumption, fluorescently labeled 
OVA-2 was added to ex vivo isolated pDCs either pretreated with oxLDL or CpGs for 12 h or 
left unstimulated. Notably, as depicted in Figure 3-35 (d), the uptake of OVA-2 by ex vivo 
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isolated pDCs was enhanced after pretreatment with oxLDL comparable to the augmented 
antigen uptake after CpG stimulation. In summary, enhanced phagocytotic capacity upon 
exposure to oxLDL may strengthen pDC-driven immune responses in atherosclerosis.  
 
3.3.4 ACTIVATION OF PDCS BY AUTOIMMUNE MECHANISMS 
Notably, pDCs are well known for their involvement in the pathogenesis of several 
autoimmune diseases (ref. to 1.2.2.2), leading to the description of two main mechanisms, 
which cause breakdown of immune tolerance resulting in pDC activation: Self-nucleic acids, 
which form complexes with the antimicrobial peptide LL37/Cramp, and DNA-specific IgG 
autoantibodies produced by autoreactive B cells, which bind self-DNA–Cramp complexes. 
As depicted in Figure 3-36 (a) treatment of ex vivo sorted pDCs with dying neutrophils, CpG or 
Cramp complexed with DNA, but not Cramp or DNA alone, induced IFNα production by pDCs. 
In line with findings by Ganguly et al.171, MHCII (Figure 3-36, b) and CD86 (Data not shown) 
expression were only altered after CpG treatment, but not after stimulation with Cramp-DNA 
complexes or dead PMN. The expression of Cramp mRNA expression was increased in aortic 
tissue of diet-fed Apoe-/- mice compared with Apoe-/- controls on normal chow (Figure 3-36, c). 
In addition, immunofluorescent stainings with an anti-Cramp antibody displayed Cramp in 
close vicinity of segment-nucleated neutrophils (white arrow heads) within atherosclerotic 
lesions (Figure 3-36, d). These findings correlate with a study by Drechsler et al.145, who 
showed neutrophil accumulation during early lesion development. Furthermore, bone marrow 
transplantation of Cramp-/- BM in Ldlr-/- recipient mice and subsequent quantification of lipid 
depositions in en face preparations of aortas and aortic roots after 4 weeks of HFD revealed a 
significant decrease in lesion formation in Cramp-/-►Ldlr-/- aortas compared to aortas of 
Cramp+/+►Ldlr-/- mice (Figure 3-36,e). In contrast, Apoe-/ -mice, receiving repetitive i. p. 
injections of Cramp during a HFD over 4 weeks, displayed a significant increase of plaque 
formation in aortic roots (Figure 3-36, f). In summary, lesional pDCs may encounter Cramp-
complexed self-DNA, the former released by activated neutrophils, while dying neutrophils 
may be the main source of self-DNA. As a consequence breakdown of immune tolerance to 
self-DNA resulting in pDC activation leads to lesion progression. 
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Figure 3-36. Cramp-DNA complexes promote lesion formation. (a) Concentration of IFNα in 
poststimulatory supernatants of FACS-sorted pDCs following stimulation for 12 h as indicated. Data are 
expressed as mean±SD; displayed are a combination of 3-5 experiment, each experiment was 
performed in duplicates. (b) Expression of MHCII in FACS-sorted pDCs stimulated for 12 h with 
indicated stimuli and assessed by FACS analysis; representative histograms with FMO controls of 3 
independent experiments are shown. (c) Cramp mRNA expression in aortas of Apoe
-/- 
mice (n=9) 
receiving HFD relative to expression in healthy 6 week old Apoe
-/-
 mice (n=5). (d) Cramp staining (red) 
detected by immunofluorescence in the aortic root of Apoe
-/-
 mice fed HFD for 12 weeks; cell nuclei are 
counter-stained with DAPI (blue); arrow heads indicate segment-nucleated neutrophils. (e, f) Lipid 
depositions were quantified in the aorta of Ldlr
-/-
 mice reconstituted with Cramp
+/+
 or Cramp
-/-
 bone 
marrow or in roots of Cramp-treated Apoe
-/-
 mice after staining with oil-red O. All mice were fed HFD for 
4 weeks. (Cramp
+/+
►Ldlr
-/-
, Cramp
-/-
►Ldlr
-/-
 n=7; control n=5, Cramp n=8). Displayed are means 
(horizontal lines) and SD,*p<0.05.***P<0.001. 
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Following the confirmation of pDC activation by Cramp-self-DNA complexes, we further 
investigated whether DNA-specific IgG autoantibody titers would be altered in Apoe-/- on HFD. 
Notably, serum anti-dsDNA antibody titers were increased in hyperlipidemic Apoe-/- mice 
receiving a HFD for 3 months compared with healthy controls (Figure 3-37; a). Subsequently, 
Apoe-/- mice receiving a PDCA1-depleting antibody showed reduced anti-dsDNA antibody 
titers compared to isotype treated control mice after 4 weeks of HFD. In contrast, anti-dsDNA 
titers were elevated in CpG- and IFNα treated Apoe-/- mice, but not in CpG-injected mice 
depleted of pDCs (Figure 3-37; b, c). Furthermore, enhanced anti-dsDNA antibody titers could 
also be observed in Apoe-/- with prolonged injections of CpGs during 8 weeks of high fat diet 
(Figure 3-37; d). In turn, diminished anti-dsDNA antibody titers were detectable in Ldlr-/- mice 
reconstituted with Cramp-/- versus Cramp+/+ bone marrow; which is in line with the reduced 
lesion size in these mice (Figure 3-37; e). Interestingly, abundant IgG-deposits could be 
detected in atherosclerotic plaques of diet-fed Apoe-/- mice, predominantly in regions of DNA 
fragmentation at the border of necrotic plaque areas (Figure 3-37; f). In order to investigate, if 
these anti-dsDNA antibodies would activate pDCs, ex vivo sorted pDCs were stimulated with 
serum of Apoe-/- mice containing high or low levels of anti-dsDNA antibody titers. Remarkably, 
serum with high titers, but not serum containing low titers of anti-dsDNA antibodies 
significantly increased IFNα production in pDCs in vitro (Figure 3-37; g). Comparable to 
stimulation experiments with Cramp-DNA complexes, the expression of MHC-II, as a 
maturation marker of pDCs, was unaltered in the presence of serum, but upregulated after 
addition of CpGs (Figure 3-37; h). Thus, auto-antibody-self-DNA complexes within lesions, 
may also contribute to pDC activation and lesion progression in atherosclerosis. 
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Figure 3-37. Anti-ds-DNA antibody generation correlates with atherosclerotic lesion formation 
and auto-antigenic protein-DNA complexes stimulate pDCs. (a) Anti-dsDNA antibody titers were 
quantified in serum of Apoe
-/- 
mice fed HFD for 12 weeks (n=18) and in healthy 6 week old Apoe
+/+
 mice 
(n=8 mice). (b, c) Further analysis of anti-dsDNA antibody serum titers were accomplished in Apoe
-/- 
mice treated with IgG, PDCA1, DOTAP (control), CpG or CpG+PDCA1 or PBS and IFNα for 4 weeks 
including HFD for this time period (n=5-10 mice). (d) Quantification of anti-dsDNA antibody serum titers 
in Apoe
-/- 
mice injected with DOTAP (control) and CpG for 4 or 8 weeks receiving a HFD for 8 weeks. 
(e) Anti-dsDNA antibody serum titers in sera of Ldlr
-/-
 mice reconstituted with Cramp
+/+
 or Cramp
-/-
 bone 
marrow after 4 weeks of HFD. (f) IgG staining (red) detected by immunofluorescence in the aortic root 
in Apoe
-/-
 mice fed HFD for 12 weeks; cell nuclei are counter-stained by DAPI (blue). (g) IFNα protein 
secretion by sorted pDCs stimulated for 12 h with PBS (control), CpGs or serum containing low (▼) or 
high (▲) anti-dsDNA titers. n=5 independent experiments. Data is expressed as mean±SD, **P<0.01, 
***P<0.01. (h) MHCII expression in sorted pDCs stimulated for 12 h with CpGs or serum with low (▼) or 
high (▲) anti-dsDNA antibody titers, assessed by FACS analysis; representative histograms with FMO, 
one representative image of 5 independent experiments is depicted. 
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4. DISCUSSION 
4.1 IRF8-DEFICIENCY EXACERBATES ATHEROSCLEROSIS 
We here show that the development of a CML-like syndrome in Apoe-/- or Ldlr-/- mice transplanted 
with bone marrow from Irf8-/- mice was associated with a striking increase in atherosclerotic 
lesion formation compared to mice reconstituted with wt bone marrow. The marked expansion of 
functionally intact PMN in peripheral blood was accompanied by their enhanced accumulation at 
sites of inflammation and plaque growth in Irf8-/- bone marrow recipients, implicating an enhanced 
release of ROS and granule components. Despite a reduction in monocyte numbers, the 
accumulation of macrophages during inflammation was unaffected by IRF8-deficiency, but was 
associated with an altered phenotype and impaired phagocytic clearance of apoptotic PMN. By 
demonstrating that the depletion of circulating PMN prevented the exacerbation of atherosclerotic 
lesion formation in Irf8-/- bone marrow recipient Ldlr-/- mice we pinpointed PMN to critically 
contribute to this phenotype. 
 
4.1.1 IRF8-/- MACROPHAGES DISPLAY IMPAIRED FUNCTIONALITY 
The infiltration of the vessel wall with immune cells is a crucial force driving the development 
of atherosclerosis.137,188 Macrophages, which are present throughout all stages of 
atherosclerosis, hold a key position in the initiation but also progression of this disease. 
Through the expression of the scavenger receptors CD68, CD204, and CD36, macrophages 
participate in the phagocytic uptake of lipids contributing to their retention in the vessel wall, as 
well as in the clearance of apoptotic cells.137,148,179,180 While moderate expression levels of 
CD68 and CD204 were unaltered, the strong surface expression of CD36 observed in Irf8+/+ 
was markedly reduced in Irf8-/- macrophages. Known to account for up to 70% of the 
accumulation of oxLDL in macrophage foam cells179, these differences might at least in part 
explain the impaired uptake of oxLDL by Irf8-/- macrophages and possibly relate to higher 
serum cholesterol and LDL levels in Irf8-/-►Apoe-/- mice after 12 weeks of HFD, which in 
addition may contribute to enhanced atherosclerosis at later stages. But also lower numbers 
of ApoE-secreting, bone marrow-derived macrophages after transplantation of Irf8-/-Apoe+/+ 
bone marrow in Irf8-/-►Apoe-/- mice compared to increased Apoe+/+ monocyte counts in 
reconstituted Irf8+/+►Apoe-/- mice could contribute to increased serum cholesterol and LDL 
levels. These differences, however, are unlikely to primarily underlay enhanced lesion 
formation in Irf8-/-recipientmice, as a very similar plaque phenotype but no changes in lipid 
levels were observed in Irf8-/-►Ldlr-/- mice after 5 weeks of diet.  
4 DISCUSSION 
 
 70 
Interestingly, while the deletion of CD36 was previously shown to protect from 
atherosclerosis189, an impaired clearance of apoptotic material has been associated with 
disease acceleration and a reduction in IL-10 production181. In line, diminished IL-10 secretion 
from Irf8-/- macrophages was observed in response to phagocytosis of apoptotic PMN but also 
in sera of Irf8-/-►Apoe-/- mice. However, protein concentrations of the clearly pro-atherogenic 
cytokines127 IFN and IL-6 were reduced in air pouches of Irf8-/- compared to Irf8+/+mice. 
Moreover, the surface expression of MHCII and CD40 were substantially diminished in Irf8-/- 
macrophages, pointing at a global insufficiency in cytokine secretion, antigen-presenting and 
immune priming capacities of this cell type, functions usually associated with 
atheroprogression127. However, anti-inflammatory properties of Irf8-/- macrophages are clearly 
outweighed by pro-inflammatory mechanisms active in mice carrying Irf8-/- bone marrow. In 
light of an essential function of IRF8 in regulating macrophage maturation173, these differences 
might also be indicative of a less mature macrophage phenotype.  
 
4.1.2 MONOCYTE EXTRAVASATION IS NOT AFFECTED BY IRF8 DEFICIENCY 
In line with their differentiation from extravasated monocytes190, the depletion of 
monocytes/macrophages in mice expressing the diphtheria toxin receptor under the control of 
CD11b or the reduction in blood monocyte levels due to the lack of important mobilization or 
survival cues was shown to reduce early plaque burden191-194. Despite a marked reduction in 
circulating monocyte numbers in mice reconstituted with Irf8-/- bone marrow, unaltered 
macrophage content and an increase in plaque formation was observed in Irf8-/-►Apoe-/- or 
Irf8-/-►Ldlr-/- mice. Similarly, the acute and chronic recruitment of monocytes to the air pouch 
and peritoneum was not impaired in Irf8-/- mice. This likely precludes severe functional deficits 
in the migratory capacity of Irf8-/- monocytes per se. An enhanced survival of Irf8-/- 
macrophages masking defects in extravasation is unlikely to occur under inflammatory 
conditions, as previous findings showed a reduction in the susceptibility to apoptosis in Irf8-/- 
myeloid cells under homeostatic conditions but not upon inflammatory stimulation with TNF.175 
In line, we did not detect any differences in the frequency of apoptotic macrophages in 
atherosclerotic lesions of Irf8-/-►Apoe-/- compared to Irf8-/-►Apoe-/- mice. It remains to be 
clarified, whether the augmented PMN extravasation and the PMN-induced inflammation in 
Irf8-/-►Apoe-/- mice provide recruitment cues that enhance subsequent monocyte influx39, thus 
compensating reduced monocyte numbers in the circulation. For instance, emigrated PMN 
release preformed granule components, which can trigger the subsequent recruitment and 
attraction of inflammatory monocytes by involvement of formyl-peptide receptors.39 
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4.1.3 PMN ACCUMULATION ACCOMPANIED BY GRANULE PROTEIN DISCHARGE 
DRIVES ATHEROSCLEROSIS IN IRF8-/- APOE-/-MICE 
Moreover, granule proteins have been shown to promote pro-inflammatory responses in 
monocytes and macrophages and induce a classical macrophage polarization.146 The 
activation and discharge of granule proteins were not impaired in Irf8-/- PMN, as determined by 
the rapid upregulation of CD11b and CD14 on extravasated PMN due to their incorporation 
from membranes of secretory vesicles and tertiary granules during discharge, or by the 
release of MPO and MMP-9 from primary and secondary granules.  
Granule proteins also exert pro-inflammatory functions in other cell types. For instance, MPO 
can limit the bioavailability of nitric oxide and can therefore contribute to the onset of 
endothelial dysfunction.195 It was also reported that MPO-generated hyperchlorous acid may 
contribute to intracoronary endothelial cell desquamation and the engenderment of a 
prothrombotic phenotype.196 Due to its proteolytic function, MMP-9 on the other hand was 
shown to contribute to the degradation and weakening of the fibrous cap ultimately promoting 
a vulnerable plaque phenotype and plaque rupture.197 Accordingly, mice devoid of MMP-9 are 
protected from atherosclerosis.198 
In addition, also ROS formation was unaltered in Irf8-/- PMN, constituting another weapon 
being at the PMN's immediate demand and proposed to be a key mediator in 
atherosclerosis.182 PMN produce large amounts of ROS via MPO, lipoxygenases, and NADPH 
oxidase, most of which are secreted extracellularly and there contribute to lipid oxidation and 
retention as well as apoptosis of endothelial cells. Furthermore, ROS enhance the expression 
of endothelial adhesion molecules contributing to leukocyte recruitment.182 
PMN are short-lived phagocytes undergoing rapid apoptosis following emigration. The rate of 
apoptosis of blood or emigrated PMN was not different in Irf8-/- compared to control mice. 
However, likely due to their enhanced accumulation, apoptotic PMN were detected in 
increased numbers in atherosclerotic plaques. The impaired clearance of apoptotic cells and 
an overload of reduced phagocytic capacities of macrophages with numerous dying PMN in 
Irf8-/-►Apoe-/- mice might in consequence lead to secondary necrosis contributing to necrotic 
core formation, perpetuation of inflammation and plaque instability.147 
Accumulating evidence suggests that PMN critically contribute to atherosclerosis.140,141,148,199 
Apoe-/- or Ldlr-/- mice transplanted with Irf8-/- bone marrow displayed a marked expansion of 
neutrophils in peripheral blood and a prominent increase in frequencies of PMN within 
atherosclerotic lesions. The accumulation of PMN was also found to be increased in air 
pouches of Irf8-/- mice, and to be proportional to the increase in circulating PMN counts. As no 
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differences in PMN numbers were observed in the air pouch or the peritoneum in Irf8+/+ 
compared to Irf8-/- mice under physiological conditions or without inflammation, these findings 
suggest that circulating PMN counts determine the rate of extravasation in the context of 
inflammation and atherosclerosis. Similarly, it has recently been shown that mice with 
neutrophilia due to blockade of CXCR4 exhibit an increased accumulation of PMN in 
atherosclerotic lesions concomitant with increased atherosclerotic burden.141 In humans it has 
furthermore been suggested that the degree of atherosclerosis and the frequency of coronary 
artery symptoms positively correlate with peripheral PMN counts.142,144,200 The rapid PMN 
mobilization and leukocytosis in response to inflammation might thus constitute a universal 
mechanism impressing an enhanced PMN influx at sites of inflammation. In the context of 
myeloproliferative diseases, however, this might implicate an acceleration of 
atheroprogression.  
 
4.1.4 MYELOPROLIFERATIVE DISORDERS DRIVE ATHEROGENESIS 
Similar to our findings, mice deficient in IRF8 or expressing a mutated Irf8 gene were shown to 
display a shift in the myeloid cell homeostasis and a CML-like syndrome, characterized by a 
marked neutrophilia and defective macrophage maturation.164,173,201 Notably, reduced IRF8 
expression has also been associated with thepathogenesis ofhuman CML202,203, resulting from 
the neoplastic generation of the BCR-ABL fusion gene. Here, IRF8 functions as a tumor 
suppressor by antagonizing the tyrosine kinase activity of BCR-ABL.178 According to our 
findings, one would suspect a higher prevalence of atherosclerosis-related diseases in 
patients with myeloproliferative diseases. Literature reports on the correlation between CML 
and atherosclerosis or its consequences, however, are scarce. One study including only a 
small number of patients found a correlation of coronary artery disease with co-existing 
myeloproliferative syndromes, which was not significant after adjustment for various risk 
factors.204 
Notably, effective therapeutic regimens are available for treatment of CML that raise IRF8 
expression, e.g. therapy with the Imatinib mesylate inhibits the tyrosine kinase of the BCR-
ABL fusion gene and subsequently restores IRF8 expression, inducing a complete cytogenic 
response in 80% of CML patients in the chronic phase.178 Preliminary experiments revealed 
that treatment with Imatinib decreased the numbers of PMN in peripheral blood of wt mice 
(Data not shown). Interestingly, treatment with Imatinib was furthermore already shown to 
reduce diabetes-associated atherosclerosis in mice.205 
A current publication by Birnberg et al.206 indicated that a defect in the DC compartment in Irf8-
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/- mice may in addition contribute to the development of a CML-like disease. Although the 
underlying feedback loop remains to be elucidated, it was proposed that peripheral DC counts 
connect to myelogenesis through soluble growth factors, such as Fms-like tyrosine kinase 3 
receptor (Flt3) ligand. In line with reduced frequencies of circulating dendritic cells, increased 
Flt3 ligand levels could be observed in serum in Irf8-/-►Apoe-/- mice (Data not shown). 
 
4.1.5 PERSPECTIVES 
Taken together, these data clearly demonstratethat the expansion of functionally intact PMN in 
ill alliance with impaired macrophage functions critically contribute to atherosclerosis and 
imply that myeloproliferative syndromes or related conditions may give rise to enhanced 
atherosclerosis. Drechsler et al.145 already showed that hypercholesterolemia-induced 
neutrophilia promotes early atherogenesis attributed to stimulation of granulopoiesis, 
enhanced bone marrow mobilization as well as reduced peripheral clearance. In line with our 
findings, Drechsler et al. did also report a correlation of increased peripheral neutrophil counts 
with the extent of early atherosclerosis formation. Notably, while hypercholesterolemia-
inducedneutrophilia may normalize by time, IRF8-deficiency results in a chronic neutrophilia, 
which may not only initiate vascular damage and atherogenesis. Yet, continuous influx of PMN 
might exacerbate inflammation in the local plaque environment aggravating disease 
progression.On the other hand, another very recent study suggests thathypercholesterolemia 
may cause leukocytosis in general, because of increased proliferation of myeloid progenitors 
in the bone marrow. The authors conclude that modulation of the cholesterol efflux pathway 
might be a promising tool for therapeutic treatment of myeloproliferative neoplasms.207 
Subsequently, medical drugs developed for one or the other may be beneficial for the 
treatment of both diseases. Thus, further studies are necessary to scrutinize a possible 
enhanced susceptibility to atherosclerosis in patients with myeloproliferative disorders. 
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4.2 AUTOANTIGENIC PROTEIN-DNA COMPLEXES STIMULATE PLASMACYTOID 
DENDRITIC CELLS TO PROMOTE ATHEROSCLEROSIS 
Beyond the detection of murine pDCs in atherosclerotic lesions, this study further 
demonstrated that specific pDC activation significantly aggravates atherosclerotic lesion 
formation, while depletion of pDCs decreases early plaque development. Furthermore, pre-
treatment of pDCs with oxLDL increases their antigen uptake capacity, leading to enhanced 
antigen specific T cell proliferation in vivo. Notably, not only oxLDL stimulation of pDCs, but 
also mechanisms accounting for breakdown of immune tolerance resulting in pDC activationin 
autoimmune diseases, could be identified for atherosclerosis. Cramp-self-DNA complexes 
stimulated IFN secretion by pDCs in vitro, while Cramp-/-►Ldlr-/- mice displayed reduced 
plaque formation. In contrast, Apoe-/- mice stimulated with Cramp exhibited enlarged 
atherosclerotic lesion development. In addition, exacerbated plaque formation was always 
accompanied by increased anti-ds-DNA antibody serum titers and stimulation of pDCs with 
high anti-ds-DNA sera in vitro induced IFN secretion. Thus, chronic stimulation of pDCs by 
modified lipoproteins and autoimmune mechanisms may critically drive inflammation in 
atherosclerosis. 
 
4.2.1 ACTIVATED PDCS INITIATE ATHEROSCLEROTIC LESION FORMATION 
Atherosclerosis, being a chronic inflammatory disease of the vessel wall, critically involves 
immune cells in its pathomechanism.127 However, definite conclusions on DC implications in 
atherosclerosis, also attributed to their multifaceted functions, are still to be drawn.153 
Recently, Niessner et al.154 identified pDCs in the shoulder region of human atherosclerotic 
lesions and correlated IFN secretion with plaque instability by inducing apoptosis of vascular 
smooth muscle cells. In addition, he and his colleagues described IFNα as an inflammatory 
amplifier inducing upregulation of TLR4 on cDCs, resulting in a synergistic effect of different 
danger signals within the two DC subsets.155 Nevertheless, in vivo studies of pDC activation 
and depletion in appropriate atherosclerotic mouse models remain elusive, which underlines 
the importance of this work. We did show that pDC activation in vivo increases plaque 
formation in initial and advanced atherosclerotic lesions. Furthermore, IFNα injections 
enhanced lesion progression, confirming the identification of IFNα as a critical disease 
trigger.An observation also reported by Levy et al.208, who examined plaque development in 
Ldlr-/- mice after repetitive IFNα injections. Moreover, increased plaque formation was 
accompanied by enhanced macrophage influx, supporting a study by Goosen et al.209, which 
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showed that type I interferon signaling promotes atherosclerosis by stimulating macrophage 
recruitment to lesions. In line with these findings, not only activation of pDCs, but already 
hyperlipidemia led to a detectable, hence increased, IFN titer compared to baseline level in 
mice sera after high fat diet treatment. This was accompanied bythe accumulation of pDCs in 
aortas of these animals. In contrast and supportive to the latter, patients with CAD display a 
decreased number of circulating pDCs, emphasizing a possible role of pDCs in plaque 
progression.210 Taken together, these findings corroborate that type I interferons progress 
atherosclerosis throughout lesion development. 
 IFN secretion by pDCs may be stimulated by various ligands, including autoantigens (also 
ref. 4.2.3), and plays a critical role in response to viral61 and bacterial211 infections. CpG 
stimulation of pDCs “mimics” such infection, although stimulation with a “real pathogen” would 
result in a much higher type I interferon response.212,213 This raises the question whether or 
not pathogen related infections drive atherosclerosis. An issue that is still a matter of 
debate.214,215 However, the sensitivity of pDCs to multiple pathogens correlates well with the 
concept of an infectious burden, highlighting the importance of numerous or chronic infections 
driving atherosclerosis, rather than pointing at one infection or pathogen.216 On the other hand 
one infectious event may be enough to break down immune tolerance.217,218 Thus, 
investigation of pathogen associated pDC activation with regard to atherosclerosis may be 
another important piece in the puzzle.  
Yet, reduced plaque formation after pDC depletion could only be observed in early 
atherosclerotic lesions, while cell depletion in mice with ongoing atherosclerosis did not 
reduce the plaque burden. These results came along with increased T cell numbers and 
dramatically enhanced IL-4 serum titers, suggesting that pDC depletion under inflammatory 
conditions may cause a complex imbalance of the immune response. Although, IL-4 is known 
to stimulate a Th2 response and induces alternative macrophage activation127,219, its role in 
atherosclerosis seems to be variable, depending on the disease stage.220 Of note, alternative 
macrophage activation may not always be beneficial, but can result in macrophage 
accumulation in inflamed tissue.208 Furthermore it is well known, that type I interferons are 
critical regulators of DC and T cell homeostasis.221 Baseline type I interferon expression222 is 
assumed to play a considerable role in the regulation of Treg homeostasis223, potentially by 
influencing their thymic selection process. The latter may explain, why the relative number of 
CD4+ CD25+ T cells was significantly decreased (Data not shown), while numbers of CD4+ T 
cells in total were increased in pDC depleted mice. Moreover and in line with the findings 
above, Apoe-/- mice transplanted with IkarosL/L bone marrow (a mouse model which lacks 
pDCs224) displayed no changes in plaque formation, but dysregulated T cell homeostasis after 
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high fat diet treatment (Data not shown). Thus, reduced type I interferon levels (beneath 
baseline) possibly cause disturbed T cell homeostasis, manifesting in increased T cell 
numbers accompanied by augmented T cell derived IL-4 serum titers and decreased Treg 
frequencies. In conclusion, this may explain why pDC depletion under inflammatory conditions 
does not reduce plaque formation. 
Recruitment of DCs into atherosclerotic lesions seems to be mediated by CCL2, CCL5 and 
fractalkine (CX3CL1), abundantly expressed in inflamed atheromas.
153 Nevertheless, one may 
only speculate, whether these mechanisms do also account for pDC recruitment in particular. 
It has been shown that pDCs not only migrate in response to CCL5, but also to CCL3, CCL25, 
CXCL9, CXCL10 and, CXCL12 depending on the pathological conditions involved.73 Though, 
recruitment assays in the context of an inflammatory air pouch model within this thesis did not 
clearly show an involvement of CCL5 in the recruitment of pDCs to sites of inflammation (Data 
not shown), which may also be explained by the recruitment model chosen. However, 
administration of IFN into the air pouch cavity did lead to an increased number of pDCs after 
4h (Data not shown). The latter may perhaps point at an autocrine feedback loop between 
pDC derived type I interferons and subsequent cell recruitment. Notably, chemerin injections 
into pouches resulted in significantly increased pDC accumulation (Data not shown), most 
likely reflecting increased pDC numbers and enhanced chemerin titers in CpG stimulated 
mice. Thus, neutrophil derived chemerin could not only be a potent chemotactic factor 
directing pDC migration in psoriasis74,225, but also drive pDC recruitment to aortic lesions. 
 
4.2.2 OXLDL CRITICALLY INFLUENCES PDC FUNCTIONS 
Modified lipoproteins, in particular oxLDL, are main triggers of atherosclerosis. OxLDL induces 
foam cell formation, alteration of nitric oxide signaling, initiation of endothelial activation, and 
expression of adhesion molecules that accelerate leukocyte homing to the site of 
atherosclerosis.226 Additionally, accumulating evidence shows that oxLDL affects DC 
migration, maturation and the expression of scavenger receptors.186,227,228 Furthermore, 
induction of hypercholesterolemia in mice triggers rapid ingestion of lipids by resident intimal 
DCs. In turn, these cells initiate early foam cell formation in atherosclerotic lesions.229 
However, similar to the lack of general data on how pDCs in detail may influence 
atherosclerosis, studies investigating the influence of oxLDL on pDCs are absent. In our 
hands pDCs were able to take up oxLDL and oxLDL-treated pDCs upregulated the expression 
of scavenger receptor CD36, which is one of the most important receptors for oxLDL 
uptake179. In contrast to cDCs186,228,230, pDCs did not increase the expression of MHCII and 
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CD86 in the presence of oxLDL, but oxLDL treatment enhanced their capacity to induce 
antigen specific T cell proliferation. An observation also reported for cDCs, which also 
maintain their ability to prime CD4+ T cells after oxLDL uptake.230,231 According to our data, 
augmented induction of T cell proliferation by oxLDL stimulatated pDCs may be explained by 
their increased antigen uptake. Though, uptake of exogenous antigen by pDCs is impaired 
compared to cDCs because of their diminished ability for phagocytosis or macropinocytosis.58 
However, pDCs possibly internalize exogenous antigens by receptor mediated endocytosis via 
specific receptors of the c-type lectin232 or siglec233 family, of which some are highly or 
exclusively expressed on pDCs234-236. Subsequently, their expression may also be affected by 
oxLDL treatment.186 Taken together, oxLDL may force pDC-driven immune responses in the 
context of atherosclerosis.  
 
4.2.3 AUTOIMMUNE MECHANISMS DRIVE PDC ACTIVATION IN ATHEROSCLEROSIS 
Besides the recognition of atherosclerosis as a chronic inflammatory disease, a growing group 
of scientists hold the opinion that it may also be an autoimmune disorder. According to the 
“Koch‟s postulates” it fulfills the criteria for an inflammation of autoimmune origin: (i) presence 
of autoantibodies or evidence of cellular reactivity to self; (ii) documentation of lymphocyte 
infiltrate in the pathologic lesion; (iii) demonstration that autoantibodies or activated T cells can 
cause tissue pathology.218 However, the reduction of atherosclerosis as being “simply” an 
autoimmune disease would not take into account other triggers such as metabolic and 
hemodynamic factors.237 But not only the disease classification may be complex also the 
(auto)antigens considered to be responsible for the autoimmune activation are multifaceted. 
Best characterized autoantigens for atherosclerosis are oxLDL and heat shock proteins 
(HSPs), particularly HSP60.218,238 Both can form immune complexes with their cognate 
antibodies and modulate inflammation in atherosclerosis.239 
 Another group of postulated immune stimulators in autoimmune diseases are nuclear 
antigens derived from apoptotic or necrotic cells, which are known to play an important role in 
the stimulation of pDCs in the pathomechanisms of psoriasis and SLE.97 In addition, both 
diseases are associated with increased prevalence of atherosclerosis.112,114 Notably, we were 
able to show that similar mechanisms may also trigger plaque development in atherosclerosis. 
We could confirm that, Cramp-DNA complexes, in line with previous findings in the 
pathogenesis of psoriasis42,171,240, stimulate IFN secretion by pDCs in vitro. As a novelty, the 
same results were obtained by pDC activation with dead PMN, emphasizing an ill-alliance of 
apoptotic neutrophils and pDCs within atherosclerotic lesions. Further evidence approving 
Cramp as a disease amplifier in atherosclerosis were revealed after analyzing plaque 
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formation in Apoe-/- mice treated with Cramp. These mice displayed an increase in plaque 
formation, while Cramp-/-►Ldlr-/- mice exhibited a decrease in lesion size. Moreover, 
supporting a study by Edfeldt et al.241, who encountered LL-37 in human atherosclerotic 
lesions, we could visualize lesional Cramp in murine plaques and corroborated enhanced 
Cramp mRNA transcripts in atherosclerotic murine aortas. Hence, complex formation of self-
DNA and antimicrobial peptides resulting in pDC activation may be a shared 
pathomechanism112 between psoriasis and atherosclerosis. Thus, increased prevalence of 
atherosclerosis in patients with psoriasis242 may be explained by chronically activated pDCs. 
 SLEis identified by complex formation between self-DNA and anti-DNA antibodies. These 
DNA containing immune complexes (IC) accumulate within various tissues leading to 
unspecific immune activation eventually resulting in breakdown of immune tolerance. One 
hallmark of SLE diagnostic is the detection of anti-nuclear antibodies (ANAs), including anti-
dsDNA antibodies.243 Interestingly, Aprahamian et al.244 already proposed defects in apoptotic 
cell clearance as pathogenic trigger in atherogenesis and SLE development in a combined 
mouse model of lupus and atherosclerosis. In contrast to this work he and his colleagues did 
not report augmented ANA levels in Apoe-/- mice on high fat diet. According to our findings, 
determination of ANAs in high fat diet fed Apoe-/- mice revealed increased ANA titers in sera of 
these mice (Data not shown). Further investigations of anti-dsDNA antibody levels in all sera 
of the mice included in this thesis even displayed significantly elevated anti-dsDNA titers in 
correlation with enhanced plaque formation. Thus, IC may also form in the context of 
atherosclerosis and DNA containing immune complexes have also been implicated in the 
activation of pDCs with subsequent IFN release.245,246 Remarkably, we were also able to 
demonstrate that sera of Apoe-/- mice with a high anti-dsDNA titer did induce IFN secretion 
by pDCs in vitro. A similar observation was made for isolated DNA containing IC from SLE 
patients.246 Noteworthy, comparable results were reported by Pertovaara et al.247, who showed 
that elevated anti-nuclear antibody titers were associated with decreased carotid elasticity in 
young Finns, which might confirm their participation in the development of early 
atherosclerosis. Ultimately, we demonstrated the presence of IgGs within atherosclerotic 
lesions, which concentrated in the plaque center highlighting their availability in inflammatory, 
growing lesions. Hence, increased pDC numbers and elevated IFN levels in SLE patients 
may be one explanation for their increased risk to develop atherosclerosis.248 
In conclusion, Cramp-induced recognition of self-DNA triggering activation of pDCs and 
secretion of IFN may be critical in promoting auto-antibody production, which in turn may 
enhance pDC activation.108,246 
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4.2.4 PERSPECTIVES 
Summarizing the novelty of the data presented and discussed above, we showed that specific 
pDC depletion or stimulation severly affects atherogenesis. Furthermore, mechanisms 
relevant to pDC activation in autoimmune diseases may be pertinent in chronic arterial 
inflammation, namely atherosclerosis. Especially further insight in the ill-alliance of neutrophils 
and their secretory products during pDC activation may improve our understanding of 
pathomechanisms underlying atherosclerosisin particular (Figure 4-1) and of autoimmune 
diseases in general.  
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Figure 4-1: Summary of potential mechanisms of pDC activation by neutrophil secretory 
products in atherosclerosis. PMN-derived ROS facilitate LDL modification leading to oxLDL 
accumulation. Lesional oxLDL may be encoutered by pDCs resulting in enhanced CD36 surface 
expression and antigen uptake by pDCs. Subsequently, augmented antigen uptake by pDCs stimulates 
increased antigen-specific T cell proliferation. In parallel, MPO reduces the bioavailability of NO and 
leads to production of HOCl. The latter may induce endothelial cell apoptosis and desquamation. 
LL37/Cramp secreted by infiltrating neutrophilsbinds self-DNA fragments released from dying cells to 
form aggregates of self-DNA–LL37/Cramp. Dying cells also set free high-mobility group box 1 protein 
(HMGB1), which binds self-DNA–LL37/Cramp complexes and promotes their association with TLR9. In 
addition, DNA-specific IgG autoantibodies produced by autoreactive B cells bind to self-DNA–
LL37/Cramp–HMGB1 complexes and potently increase their translocation into TLR9-containing 
endosomes in pDCs. These complexes activate pDCs and lead to a robust type I interferon production. 
In turn, IFNα activates cDCs, which produce proinflammatory cytokines and induce antigen-specific T 
cell proliferation (extracted from
97,148,153
). 
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Overall, the aberrant conversion of self-nucleicacids into ligands for TLR7/9 in pDCs may 
represent a common step of several pathogenic cascades not only in psoriasis and SLE, but 
possibly also for other autoimmune diseases.249 Consequential therapeutic approaches 
targeting e.g. the specific release of granule proteins (e.g. LL37) may be a promising tool for 
diseases in this context. Hence, one should also not ignore that the mechanisms discussed 
above may only be true for TLR9, although TLR7 is also involved in nucleic acid recognition. 
Shlomchik et al.250 already reported opposing roles of TLR7/9 in the pathogenesis of SLE. On 
the other hand, it should be kept in mind that the complete depletion of pDCs, beyond the 
increased susceptibilityto viral infections, seems to disturb T cell homeostasis. Thus, 
therapeutic approaches should aim carefully at very specific drugs, only intervening with 
distinct functions rather than blocking or depleting whole cell subsets. 
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5. SUMMARY 
This study focuses on the understanding of the pathophysiological role of neutrophils and 
plasmacytoid dendritic cells in atherosclerosis.  
 Atherosclerosis is now agreed to be a chronic inflammatory disease of the vessel wall 
driven by intense immunological activity, of both, innate and adaptive immunity. Whereas 
monocytes/macrophages are of paramount importance, polymorphonuclear neutrophilic 
leukocytes (PMN) have recently also been implicated in lesion formation. Given the expansion 
of these cell types in myeloproliferative disease, we here investigated atherosclerotic lesion 
formation in Interferon regulatory factor 8-deficient (Irf8-/-) mice. Thechronic myelogenous 
leukemia (CML)-like phenotype with expanded PMN but reduced frequencies of monocytes in 
bone marrow and peripheral blood in atherosclerosis-prone apolipoprotein E-deficient (Apoe-/-) 
mice reconstituted with Irf8-/- bone marrow was associated with an increased lesional 
accumulation of PMN, apoptotic cells, a more pro-inflammatory plaque phenotype, and 
exacerbated atherosclerotic lesion formation in comparison to Irf8+/+ bone marrow-recipient 
Apoe-/- mice. Although accumulating in equal numbers at sites of inflammation and plaque 
growth, Irf8-/- macrophages were defective in phagocytosis of apoptotic cells and lipids as well 
as cytokine production, contrasting unaffected reactive oxygen species formation, and 
discharge of PMN granule components by Irf8-/- compared to IRF8+/+ PMN. Depletion of PMN 
in atherosclerotic mice reconstituted with Irf8-/- bone marrow abrogated increased lesion 
formation. These data indicate that the expansion of functionally intact PMN in ill alliance with 
impaired macrophage functions critically contribute to atherosclerosis and imply that long-
standing CML-syndroms may associate with enhanced atherosclerosis. 
 Dendritic cells are very heterogenous group of antigen presenting cells and their role in 
atherosclerotic lesion formation is not clear. Even less is known about plasmacytoid dendritic 
cells (pDCs) in this context. Thus, this study wanted to unravel the role of pDC in 
atherosclerosis. Besides the detection of murine pDCs in atherosclerotic lesions, it could be 
further demonstrated, that specific pDC activation significantly aggravates atherosclerotic 
lesion formation, while depletion of pDCs decreases early plaque development. Furthermore, 
pre-treatment of pDCs with oxLDL increases their antigen uptake capacity, leading to 
enhanced antigen specific T cell proliferation in vivo. Notably, not only oxLDL stimulation of 
pDCs, but also mechanisms accounting for breakdown of immune tolerance resulting in pDC 
activation in autoimmune diseases, could be identified for atherosclerosis. Cramp-self-DNA 
complexes stimulated IFN secretion by pDCs in vitro, while Cramp-/-►Ldlr-/- mice displayed 
reduced plaque formation. In contrast, Apoe-/- mice stimulated with Cramp exhibited enlarged 
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atherosclerotic lesion development. In addition, exacerbated plaque formation was always 
accompanied by increased anti-ds-DNA antibody serum titers and stimulation of pDCs with 
high anti-ds-DNA sera in vitro induced IFN secretion. Thus, chronic stimulation of pDCs by 
modified lipoproteins and autoimmune mechanisms may critically drive inflammation in 
atherosclerosis. 
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6. ZUSAMMENFASSUNG 
Die Atherosklerose ist als eine chronische Entzündung der Gefäßwand zu verstehen, in deren 
Pathomechanismus die inflammatorische Rekrutierung leukozytärer Zellen eine zentrale 
Bedeutung für die Initiierung und Progression atherosklerotischer Läsionen spielt. 
 Die Rolle von Phagozyten in der Pathophysiologie der Atherosklerose, vorrangig 
Monozyten und Makrophagen, unterlag in den letzten Jahrzehnten weitreichenden 
Untersuchungen. Der kausale Beitrag von Neutrophilen Granulozyten (NG) zur Atherogenese 
ist dagegen weitestgehend unverstanden. Epidemiologische Studien weisen auf eine positive 
Korrelation zirkulierender NG-Zahlen und der Inzidenz von koronaren Herzerkrankungen hin. 
Daher werden hier atherosklerotische Apolipoprotein E-defiziente (Apoe-/-) Mäuse mit dem 
Knochenmark Interferon-regulierenden-Faktor-8-defizienter (Irf8-/-) Tiere transplantiert. Mit 
erhöhter Zahl peripherer NG, weisen letztere ein Blutbild auf, das dem der chronisch 
myeloischen Leukämie (CML) ähnelt. Mit Hilfe dieser Transplantation kann man somit die Zahl 
der NG im atherosklerotischen Kontext deutlich erhöhen, um so ihren Einfluss auf die 
Atherogenese besser untersuchen und verstehen zu können. In dieser Arbeit konnte gezeigt 
werden, dass Apoe-/- Tiere, die mit Irf8-/- Knochenmark transplantiert wurden, eine deutlich 
vermehrte Plaquebildung zeigen. Durch die Reversion der Läsionsgröße in NG-depletierten 
Tieren konnte der kausale Beitrag von NG in diesem Modell bewiesen werden. Insbesondere 
die durch NG freigesetzten Granulaproteine und die Akkumulation apoptotischer NG im 
nekrotischen Kern des Plaques trugen zur erhöhten Läsionsbildung bei. Aus diesen 
Ergebnissen lässt sich eindeutig ableiten, dass NG eine entscheidende Rolle bei der 
Entstehung und Progression von atherosklerotischen Läsionen spielen und eine Erhöhung 
ihrer Zahl, nicht nur für Patienten mit CML, sondern auch im Rahmen anderer chronischer 
Inflammationen einen kardiovaskulären Risikofaktor darstellen. 
 Dendritische Zellen sind spezialisierte Antigen-präsentierende Zellen, die zur Attraktion und 
Aktivierung von T-Zellen beitragen.Allerdings handelt es sich hier um eine sehr heterogene 
Zellpopulation mit mehreren Subtypen. Im Fokus dieser Arbeit stehen die plasmazytoiden 
dendritischen Zellen (pDC). Diese sind durch ihre Fähigkeit gekennzeichnet grosse Mengen 
proinflammatorischer Typ I Interferone als Antwort auf virale und bakterielle Pathogene 
auszuschütten. Ihre Bedeutung in der Atherosklerose ist kaum untersucht. Es war daher Ziel 
dieser Doktorarbeit zum Einen abzuklären, ob pDC in murinen Läsionen von Apoe-/- Mäusen 
nachweisbar sind. Weiterhin sollte untersucht werden, ob eine Depletion oder Stimulation 
dieser Zellpopulation in vivo die Plaquentwicklung beeinflusst. Nach Auswertung der 
Stimulationsstudien in Apoe-/- Tieren zeigte sich eine signifikant erhöhte Plaqueentwicklung 
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und ließ die Frage offen, welche Mechanismen in vivo ursächlich zu einer Stimulation von 
pDC führen können. Neben den bereits beschriebenen Ursachen, die zur Entstehung von 
Atherosklerose beitragen, wird im Kontext neuerer Studien auch diskutiert, welchen Einfluss 
autoimmune Mechanismen auf die Entwicklung von Atherosklerose haben. Die pathologische 
Relevanz von pDC und die von ihnen ausgeschütteten Typ I Interferone ist bereits für 
verschiedene autoimmune Erkrankungen wie z.B. Psoriasis und Sytemischen Lupus 
Erythematodes (SLE) beschrieben. Die dort gezeigten Pathomechanismen sind auch für die 
Entstehung von Atherosklerose von Bedeutung. Im Rahmen dieser Arbeit konnte gezeigt 
werden, dass z.B. die Konzentration von anti-Doppelstrang-DNA Antikörpern (a-dsDNA-AK), 
die an körpereigene DNA binden und somit zur Bildung von Immunkomplexen (IC) beitragen, 
in Apoe-/- Tieren unter fettreicher Diät erhöht ist. Ausserdem weisen Apoe-/- Tiere unter 
fettreicher Diät per se einen erhöhten Type I Interferon Spiegel auf. Darüber hinaus konnte in 
vitro nachgewiesen werden, dass IC-reiche Seren pDC aktivieren. Ähnlich verhält es sich mit 
Komplexen aus körpereigener DNA und dem antimikrobiellen Peptid LL-37/Cramp 
(human/murin). Hier konnte u.a. gezeigt werden, dass Cramp-/- Mäuse weniger Plaque 
entwickeln. Aus diesen Ergebnissen lässt sich eindeutig ableiten, dass die konstante 
autoantigene Stimulation von pDC und die damit verbundene Sekretion von Typ I Interferonen 
zur Entstehung und Progression von atherosklerotischen Läsionen beiträgt.  
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